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ABSTRACT 
Urinary tract infections (UTIs) are common, with nearly half of all women and 
12% of men experiencing at least one UTI in their lifetime. While most UTIs seldom 
cause life-threatening or long-term health problems, the regularity with which they occur 
generates a substantial economic and public health burden. Over 80% of these infections 
are caused by a heterogeneous group of uropathogenic Escherichia coli (UPEC) strains, 
and patients are generally treated with a course of antibiotics to prevent more serious 
infection. However, the emergence and spread of antibiotic resistance mechanisms, such 
as extended-spectrum beta-lactamases and carbapenemases, complicate the successful 
long-term treatment of UTI and increase the potential for serious infection. As a result, 
novel therapeutics and preventive approaches to UTI, such as vaccination, are sought. 
We hypothesized that targeting nutrient acquisition in pathogenic bacteria, 
specifically systems that acquire iron, could provide a novel vaccine target to prevent 
UTI. Using a murine model of infection and recombinant UPEC antigens, we identified 
the yersiniabactin receptor, FyuA, as a protective vaccine candidate. Intranasal 
immunization with FyuA induced a robust and long-lived humoral immune response that 
correlated with protection against UPEC colonization in the kidneys and development of 
acute pyelonephritis. In addition, using a UPEC mutant unable to acquire yersiniabactin 
during infection, we established the yersiniabactin receptor as a UPEC virulence factor 
during cystitis and pyelonephritis, a fitness factor during bacteremia, and the surface-
accessible target of the experimental FyuA vaccine. We were also able to validate the 
 xvii 
expression of iron acquisition systems, including the yersiniabactin system, during 
natural human infection by quantifying RNA transcripts, directly stabilized from E. coli 
in the urine of women with uncomplicated cystitis, by RNAseq analysis. These findings 
provide a foundation for the development of a vaccine to prevent UPEC UTI by targeting 
the yersiniabactin receptor, and reinforce support for the yersiniabactin system as a 
narrow-spectrum therapeutic target to combat multidrug-resistant pandemic clones of the 
family Enterobacteriaceae. 
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CHAPTER 1 
INTRODUCTION 
 
 
Author’s Note: This chapter is a modified version of the previously published review article: 
Brumbaugh AR and Mobley HLT. Preventing Urinary Tract Infection: Progress toward an 
effective Escherichia coli vaccine. 2012. Expert Rev Vaccines 11:663-676 
 
Urinary tract infection 
A public health burden. 
Despite the regular flow of urine, formidable physiological barriers, and a robust 
array of host defenses, the human urinary tract remains one of the most common sites for 
bacterial infection (1). Roughly half of all women and 12% of men will experience a 
urinary tract infection (UTI) in their lifetime (Figure 1-1) (2). Approximately a quarter of 
these women will have a recurrent infection within 6 to 12 months (3). The high 
incidence of infection results in 11 million physician office visits and 1.7 million 
emergency room visits annually in the United States alone (4). On a population scale, the 
consequence of frequent UTI amounts to a substantial fiscal public health burden. In 
2000, Americans spent a staggering $3.5 billion treating UTIs (5). 
Classifications. 
The majority of UTIs begin as a bladder infection, clinically termed cystitis, 
which results from pathogenic bacteria, colonizing the perineum, traversing the urethra 
and successfully infecting the bladder. If cystitis is left untreated, colonizing bacteria can 
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ascend the ureters to cause a secondary infection in the kidneys, acute pyelonephritis, 
which can result in renal scarring and permanent kidney damage (6). In severe cases of 
pyelonephritis, invading bacteria can breach epithelial and endothelial barriers in the 
kidney to gain access to the bloodstream (bacteremia) leading to systemic infection and 
sepsis, a serious and sometimes fatal complication (7). UTIs occurring in individuals with 
no physical abnormalities of the urinary tract or medical devices that would circumvent 
natural host defenses, such as a catheter, are classified as “uncomplicated” and are the 
most common type of UTI (1). Uncomplicated UTIs are unique among bacterial 
infections in that they occur most frequently among otherwise healthy women between 
the ages of 18 and 29 years (1).  
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Figure 1-1. Urinary tract infection among women is extremely common. Roughly 
13% of women between the ages of 18 and 90 years of age will have an annual incidence 
of urinary tract infection. Based on 2010 United States census data, an estimated 15 
million women will have a urinary tract infection annually in the United States (8). 
Percentages are represented by circle area. 
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Uropathogenic Escherichia coli. 
Although there are a number of bacterial genera capable of infecting the human urinary 
tract, including Proteus, Enterococcus, Klebsiellae, and Staphylococcus spp., greater than 
80% of uncomplicated UTIs are caused by a heterogeneous group of Escherichia coli 
strains, termed uropathogenic Escherichia coli (UPEC) (9). Genotypic and phylogenetic 
analyzes provide evidence that UPEC is actually part of a larger group of pathogenic E. 
coli strains collectively termed extraintestinal pathogenic E. coli (ExPEC) that include 
meningitis-associated E. coli and sepsis-associated UTI (10). UPEC are distinct from 
fecal commensal strains of E. coli found in the gastrointestinal tract, in that their genomes 
frequently encode a war chest of additional genes and virulence factors that facilitate 
infection of the host urinary tract (9, 11, 12). These additional genes may encode toxins, 
adhesins, iron acquisition systems, additional metabolic enzymes, and structural 
components that enable UPEC to take advantage of a unique and otherwise sterile host 
environmental niche (Figure 1-2)(13).  
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Figure 1-2. Classes of UPEC Vaccine Targets. Classes of UPEC vaccine targets 
include fimbrial adhesins, surface polysaccharides, outer membrane iron receptors, and 
toxins. 
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Current standard treatment for UTI: Antibiotics 
The problem of decreasing efficacy. 
Antibiotics currently represent the most commonly prescribed treatment for UTI 
and patients that suffer from recurrent infection, having three or more infections a year, 
may be prescribed antibiotics prophylactically (14). In individuals plagued with 
persistently recurring UTI, which includes roughly 3% of women, rising rates of 
antibiotic resistance to first- and second-line therapies can make UTI treatment especially 
challenging, forcing physicians to reach for more expensive and sometimes less effective 
drugs (15-17) (Figure 1-1). For example, in Turkey, the first-line antibiotic for UTI, 
trimethoprim-sulfamethoxazole (TMP-SMX), was used extensively beginning in the 
early 1980s. By the early 1990s uropathogen resistance rates to TMP-SMX had increased 
to above 50% leading to therapeutic failure and physicians to adopt quinolones as the 
preferred therapeutic for UTI (18). In the decade following the shift towards quinolones 
for UTI treatment, uropathogen resistance rates to quinolones in Turkey spiked almost 
30% (18). In the United States and Canada, approximately 10-25% of uncomplicated UTI 
isolates are resistant to TMP-SMX, and in Spain and Portugal the resistance rate can be 
as high as 35% (16, 19, 20). Even more troubling is the rate of multidrug resistance 
among UPEC isolates, which has risen as physicians adapt prescription choices to 
address shifting microbial susceptibilities (21). A recent international Antimicrobial 
Resistance Epidemiological Study on Cystitis (ARESC) documented over 10% of cystitis 
E. coli isolates to be resistant to at least three different classes of antimicrobial agents 
(22). 
  7 
Secondary infections and co-morbidities. 
In addition to contributing to a rise in antibiotic resistance, repeat antibiotic 
treatment of UTI frequently results in added co-morbidities that drive-up medical costs 
and substantially diminish patient quality of life. Indeed, antibiotic therapy may 
deleteriously affect a patient’s commensal microbiota and lead to secondary infections 
post-treatment such as vaginal yeast infection and gastrointestinal infection (23-25). 
Individuals that undergo repeat antibiotic treatment are also at increased risk for carrying 
additional pathogens resistant to multiple antibiotics, further complicating medical care 
(26). In an effort to provide a more effective and less costly alternative to antibiotic 
therapy for UTI management, progress has been made in the development of a preventive 
vaccine to target the most prominent uropathogen, UPEC. 
 
UPEC Vaccine Development 
Although it appears that a prior UTI fails to elicit a protective host immune 
response and uropathogen heterogeneity complicates vaccine design, data from animal 
model studies offer encouragement for successful UPEC vaccine development (27, 28). 
Immunization with UPEC antigens can stimulate a mucosal immune response that may 
be effective at preventing experimental UTI, and increases in urinary and serum antibody 
titers correlate with reductions in bladder bacterial load and infection duration (29-33). 
With continued effort, these data provide encouragement that an effective UPEC vaccine 
can be developed.  
Design considerations. 
A successful UPEC vaccine will likely require the following design 
  8 
considerations. The target of a UPEC vaccine will need to be highly immunogenic, 
expressed by the bacterium in vivo (i.e., during infection) and be surface-exposed on the 
bacterium in order to be accessible and recognized by the host immune system (34). In 
addition, ideal vaccine candidates should be pathogen-specific, as to avoid targeting host 
commensal E. coli in the gastrointestinal tract. The heterogeneous nature of the UPEC 
population will also need to be considered, as a required core set of virulence factors 
common to all UPEC isolates has yet to be identified. Designing a UTI vaccine that can 
be effective against such a diverse pathogen population as UPEC may prove to be a 
considerable challenge. Furthermore, an effective vaccine for UTI will need to generate a 
robust mucosal adaptive immune response in the urinary tract. To better enable a strong 
mucosal immune response, research into novel antigen delivery systems, routes of 
immunization, and adjuvants such as modified heat labile toxin, engineered outer 
membrane vesicles, and mast cell activators, among others, have been ongoing (35-39).  
Modeling infection. 
Much of our understanding of UPEC pathogenesis and our ability to evaluate 
UPEC vaccine designs has relied on the use of a mouse model of experimental UTI (for a 
recent review of mouse models of UTI see Hung et al. (40)). The use of mice to model 
UTI has proven to be an invaluable resource for advancing our knowledge of bacterial 
infection in the mammalian host. However, like all animal models of human disease, 
mouse models of UTI are not without limitations. Environmental, behavioral, and 
physiological differences between mice and humans, including differences in the urinary 
tract, such as urine concentration and contents (mouse urine contains more protein and is 
more concentrated compared to human urine), require that we avoid direct comparison 
  9 
between human and mouse studies (41). Indeed, studies comparing UPEC gene 
expression between bacteria obtained from experimental UTI in the mouse and active 
human UTI have identified differences, indicating unsurprisingly that artificial infection 
of the mouse does not directly equate with natural infection in humans (42). Although 
mouse UTI models have been instrumental for UPEC vaccine design and we will include 
data from both animal models and human studies in this review, it is important to 
differentiate between data obtained through experimental infection in animals and those 
obtained through human studies. In the following sections, various UTI vaccination 
strategies as well as the future directions of the UPEC vaccine field will be discussed. 
 
UPEC vaccine targets and formulations 
Surface polysaccharides. 
The carbohydrate-rich cell surface of UPEC, like all Gram-negative bacteria, 
contains an abundance of various polysaccharides. The external leaflet of the bacterium’s 
outer membrane contains lipopolysaccharide (LPS; O antigen) and virtually all UPEC 
strains are covered in a protective polysaccharide coat, or capsule (K antigen). O-
antigenic LPS, and to a greater extent, K-antigenic capsular polysaccharide are virulence 
factors that allow UPEC to evade host immune system assaults, such as 
opsonophagocytosis, complement-mediated killing, and damage by antimicrobial 
peptides (43, 44). Furthermore, recent work suggests that UPEC capsular polysaccharide 
and O antigen may cloak sub-capsular epitopes on the bacterial cell surface, obscuring 
them from recognition by host antibodies, demonstrating yet another mechanism by 
which surface polysaccharides may interfere with the host immune response (45).  
  10 
Early UTI vaccine studies focused on surface polysaccharides as targets for 
immunization, and some O and K antigen-based UPEC vaccines did elicit a protective 
immune response in animal models of ascending UTI (Table 1-1)(46-50). However, 
substantial antigenic heterogeneity exists among Escherichia coli surface 
polysaccharides, including 167 different O serogroups and greater than 80 polysaccharide 
K antigens (51). Although certain K (K1, K5, K30, K92) and O (O1, O2, O4, O6, O7, 
O8, O16, O16/72, O18, O25, O50, and O75) antigenic groups are more prevalent among 
uropathogenic strains, designing a surface polysaccharide-based UPEC vaccine that can 
be effective against all UPEC serotypes is extremely challenging (52). In addition, many 
UPEC capsular polysaccharides are poorly immunogenic; camouflaged from the adaptive 
immune system by having a shared structural identity with the host. For example, the 
capsular antigen K1, which is present in an estimated 30% of pyelonephritis UPEC 
strains, is formed by repeating units of α-(2-8)-linked polysialic acid (52). An identical 
host structure is found in the carbohydrate portion of human neonatal neural cell adhesion 
molecule (n-CAM), which plays an important role in the organization of neural tissue 
(53). The adaptive immune system has protective mechanisms to prevent the generation 
of self-specific antibodies, and as a result, α-(2-8)-linked polysialic acid-specific 
antibodies are inefficiently produced, allowing K1-positive UPEC to avoid host adaptive 
immune detection (54). Other UPEC surface polysaccharide antigens, such as capsular 
antigen K5, display similar molecular mimicry, and their poor immunogenicity coupled 
with high heterogeneity pose a substantial barrier to the development of a polysaccharide-
based UTI vaccine (55).  
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Whole cell and cell lysate formulations. 
 Vaccinating with whole or lysed fractions of inactivated pathogens can be an 
effective method to generate protective immunity and a number of successful vaccines 
against human pathogens including Bordetella pertussis (whooping cough), Vibrio 
cholerae (cholera), and Salmonella typhi (Typhus) contain killed whole bacteria (56). 
There are four standardized whole cell/cell lysate-based vaccines that have been tried for 
UTI with limited success (Table 1-2).  
Urovac® (Solco Basel AG, Birsfelden, Switzerland & Protein Express, Cincinnati, 
Ohio, USA). The first such vaccine, Urovac®, was designed to provide broad protection 
by containing 10 heat-killed uropathogens: 6 UPEC strains, and one strain each of 
Proteus mirabilis, Morganella morganii, Enterococcus faecalis, and Klebsiella 
pneumoniae. The UPEC strains added to the Urovac® formulation possess several 
virulence factors, including hemolysin, type 1, P, and S fimbrial adhesins, cytotoxic 
necrotizing factor 1, several siderophores systems, the E. coli CFT073 pathogenicity 
island marker, and display the serotypes O: 1, 4, 6, 17, 75, 77; K: 1, 3, 5, 13, 95, and H: 
1, 5, 7, 33 (57). Rodents immunized with Urovac® intramuscularly were protected for up 
to 20 weeks from experimental challenge by Urovac® homologous strains and some 
heterologous strains (strains that do not share any of the same O, K, or H antigens as the 
vaccine strains) (29, 30). Women volunteers with a history of recurrent UTI experienced 
a statistically significant reduction in recurrent infection (28 infections in 23 patients out 
of 202 immunized) in the 12 months following intramuscular injections of Urovac® (once 
weekly for 3 consecutive weeks), than women that did not receive the vaccine (84 
infections in 47 patients out of 198) (58). Adverse side effects reported after Urovac® 
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injection were comparable to other bacterial vaccines, such as the DTaP vaccine for 
diphtheria, tetanus and pertussis, including redness at injection site (25% of patients), 
pressure (9%), pain (5%) and fever to 38ºC (3.5%) (58, 59). Subsequent trials delivered 
Urovac® vaginally, either with a vaginal suppository or an oil emulsion, to reduce the risk 
of endotoxin toxicity and adverse side effects, and to stimulate a more robust local 
mucosal immune response in the urinary tract (60). Phase II and extended Phase II 
clinical trials evaluating the efficacy of vaginally administered Urovac® found that 
women who received 6 total doses of vaccine, on weeks 0, 1, 2, 6, 10 and 14, gained 
short term protection from infection, having significant delays to reinfection during the 
first 8 weeks of the study in comparison to women who received placebos (61-64). 
However, over the full course of the six-month study, Urovac® immunization did not 
provide significant long-term protection from UTI or increase mean levels of UPEC-
specific serum, urinary, or vaginal antibodies (61-64). Interestingly, although the average 
number of UTIs caused by any bacterial strain during the 6-month trial period was not 
significantly different between the vaccinated and placebo groups with 1.1 and 1.5 
infections per patient respectively, the number of E. coli-caused UTIs was significantly 
decreased in the Urovac® vaccinated group (61-64). Of the women receiving Urovac®, 
72% remained free from UTIs caused by E. coli, compared to women given placebos, of 
which only 30% remained free from E. coli-caused UTIs, suggesting that Urovac® may 
be successful in reducing the incidence of E. coli-caused UTIs in susceptible women. In 
addition, even with a vaginal route of delivery, some of the women reported adverse side 
effects, including single occurrences of low-grade fever 8% (4/50), a burning sensation 
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shortly after treatment 12% (6/50), nausea 8% (4/50), vaginal bleeding 8% (4/50), or 
vaginal rash 8% (4/50)(64). 
OM-89/Uro-Vaxom® (OM Pharma, Myerlin, Switzerland). The second such 
standardized formula is Uro-Vaxom®, a lyophilized mix of membrane proteins from 18 
UPEC strains that has been approved for use as a human therapeutic in Switzerland since 
1988 and marketed and sold in almost 40 countries worldwide, excluding the United 
States and Canada. Uro-Vaxom® is prescribed as daily oral capsule and several double-
blind, placebo-controlled clinical studies have evaluated the vaccine’s safety and efficacy 
(65-69). A statistical meta-analysis of five clinical studies, involving 601 female 
participants given 90 days of treatment, showed Uro-Vaxom® to be significantly more 
effective than a placebo in preventing recurrent UTI (70). In a multicenter clinical trial 
funded by OM Pharma, women with a history of recurrent UTI were administered a daily 
oral capsule of Uro-Vaxom® for 90 days, given 3 months without treatment, and then 
boosted with a daily dose for 10 days in the beginning of months 7, 8, and 9 (68). After 
12 months, women given Uro-Vaxom® experienced a statistically significant reduction in 
UTI recurrences (185 recurrences in 93 patients out of 220 total) in comparison to those 
given placebos (276 recurrences in 122 patients out of 215 total) (68). In addition, 
patients given Uro-Vaxom® experienced a reduction in the frequency in the signs and 
symptoms of UTI, including dysuria (painful urination), bacteriuria (presence of bacteria 
in the urine), and leukocyturia (presence of leukocytes in the urine) in comparison to 
women receiving placebos, although this reduction was only statistically significant 
during one of the 6 follow-up visits (68). Patient tolerance of Uro-Vaxom® is reported to 
be good with the most frequent adverse events being headache followed by 
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gastrointestinal events including pain and nausea and skin reactions (68, 69). Although 
Uro-Vaxom® does appear to reduce the incidence of recurrent UTI, with limited toxicity 
issues, the required daily administration may create problems with patient compliance. 
Urvakol (Institute of Microbiology, Prague, Czech Republic) & Urostim 
(National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria). The third and 
fourth standardized whole cell vaccines, Urvakol and Urostim, are administered as daily 
oral tablets containing mixtures of inactivated uropathogens. Both formulations contain 
strains of E. coli, P. mirabilis, and E. faecalis, although Urvakol also includes a strain of 
Pseudomonas aeruginosa, whereas Urostim contains K. pneumoniae. Data from animal 
and patient studies demonstrate Urvakol and Urostim to have immunostimulating activity 
as measured by cytokine production and the presence of vaccine-specific antibodies in 
the serum, urine and saliva of patients after immunization (71-73). However, the ability 
of either vaccine to prevent recurrent UTI has not been established as well-structured 
clinical trials have yet to be completed.  
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Genetically engineered strains. 
In addition to the whole cell/cell lysate, inactivated UTI vaccines being designed 
and tested in Europe, vaccines based on genetically modified strains of UPEC are also in 
development (Table 1-3). To determine if UPEC’s poorly-immunogenic surface 
polysaccharides impede the generation of an optimal host humoral response, Russo and 
colleagues immunized mice with a genetically modified isogenic strain of pathogenic E. 
coli, termed CP923, that is unable to produce capsule or the O antigen of LPS due to a 
transposon-insertion into a gene that encodes for an enzyme involved in rhamnose 
biosynthesis (76). Mice immunized intranasally with formalin-killed CP923 generated a 
significantly greater overall humoral immune response, as measured by serum antibody 
levels, than mice immunized with the wild-type parental strain CP9 (76). In addition, 
immunization with CP923 generated significantly greater levels of antibodies directed 
against non-capsular and non-O-antigenic epitopes, a desirable outcome for a vaccine 
directed against the highly heterologous UPEC population (76). However, when the 
formalin-killed CP923 vaccine was tested in an intravenous sepsis model of infection, 
mice intranasally immunized with CP923 were not significantly protected from 
experimental infection by CP9, in comparison to PBS-immunized controls (45). Data 
from in vitro binding and bactericidal assays suggest that the failure of the CP923 vaccine 
to protect against CP9 infection, despite generating high serum antibody titers, may be 
due to interference by CP9 surface polysaccharides (45). Since UPEC strains are 
generally positive for capsule and O antigen, the potential of surface polysaccharides to 
mask non-polysaccharide epitopes and reduce the efficiency of antibody binding, may 
  18 
provide additional motivation to identify capsular antigens or vaccine targets that are 
external to the capsule.  
Employing a vaccine strategy with a similar genetically modified E. coli strain 
with impaired surface polysaccharide expression, Billips and coworkers (77) assessed the 
use of a live-attenuated UPEC vaccine to prevent UTI. The authors produced an 
attenuated mutant UPEC strain unable to persist in the host urinary tract due to a targeted 
deletion of a gene that encodes an O antigen ligase (waaL), an enzyme required for 
joining the variable O antigen to the LPS lipid A-core during biosynthesis (77). Mice 
inoculated with the live-attenuated UPEC strain (NU14 ΔwaaL), via a urinary catheter to 
the bladder, were protected from experimental UTI challenge with the wild type parental 
strain NU14, as well as a range of clinical UPEC isolates including CFT073 (77). 
Promisingly for UPEC vaccine development, although the live-attenuated vaccine strain, 
NU14 ΔwaaL, failed to persist longer than two-weeks in the mouse bladder after 
inoculation, the protective immunity generated post-immunization lasted at least eight 
weeks after vaccination (77). 
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Targeting UPEC adherence. 
UPEC encode a wide variety of adhesins, a general term used to describe 
extracellular proteins that facilitate bacterial attachment to, or invasion of host cells, such 
as fimbriae or pili. Indeed, fimbrial adhesins were among the first recognized UPEC 
virulence factors and the genomes of UPEC isolates generally contain many more 
fimbrial operons (8.3± 1.3) than those of commensal E. coli strains (2.0 ±2.3) (78). For 
example, the genome of the prototypical UPEC strain CFT073 encodes 12 putative 
fimbrial operons (12). Many of these fimbriae enable colonization of the host urinary 
tract and it was theorized that blocking bacterial adherence to host epithelial cells by the 
binding of antibodies would prevent colonization (79). Naturally, the critical role of 
adherence during infection has made fimbrial adhesins a prime target for UPEC vaccines. 
UPEC genomes generally encode multiple fimbriae. Thus far, however, only a small 
subset of UPEC fimbriae has been evaluated for use in a UTI vaccine, including P, Dr, 
and type 1 fimbriae (Table 1-4). 
The UPEC adhesin, PapG, which is the tip adhesin on P fimbriae, binds to 
Gal(α1-4) Gal-specific glycosphingolipids on kidney epithelium (P blood group antigen) 
and likely plays an important role in UPEC human kidney colonization (80). Vaccination 
studies using P fimbrial subunits in murine and primate models of ascending UTI found it 
to be effective in preventing kidney infection (81-83). However, P fimbriae has a limited 
role during UPEC bladder colonization and as a result, vaccines targeting the P fimbrial 
adhesion, PapG, will need to be combined with additional components that can provide 
adequate protection from infection in the bladder.  
Dr fimbriae bind to type IV collagen and decay-accelerating factor (DAF/CD55) 
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on the tubular basement membrane and Bowman’s capsule of the human kidney and 
contribute to UPEC pathogenesis in animal models of UTI (84, 85). Mice experimentally 
infected with a strain of UPEC, positive for Dr fimbriae, maintained higher and more 
prolonged kidney bacterial loads and developed significantly more tubulointerstitial 
nephritis than mice infected with a Dr fimbriae knockout mutant (86). Vaccinating mice 
with purified Dr fimbriae produced high titers of serum anti-Dr antibodies and 
significantly reduced experimental UTI-associated mortality, but did not affect the rate of 
bladder or renal colonization (87). Pre-incubating Dr+ UPEC with Dr-immunized mouse 
sera resulted in an observable reduction in bacterial adherence to mouse bladders and 
kidneys, although the same UPEC anti-binding activity was not observed when Dr+ 
UPEC were pre-incubated with the urine from Dr-immunized mice (87). Further study is 
needed to fully test the potential of Dr fimbria as a UPEC vaccine target as it is possible 
that modifying the method or route of Dr antigen delivery may improve vaccine efficacy.  
The type 1 fimbrial adhesion FimH mediates UPEC adherence to bladder 
epithelial cells by binding to mannose residues on uroplakin, a major structural 
component of the bladder epithelium (88). In the mouse, type 1 fimbria is a particularly 
important UPEC virulence factor, as its expression greatly enhances UPEC binding and 
colonization of the murine bladder during experimental UTI; a process that can be 
outcompeted by administering a competitive inhibitor of FimH, such as methyl α-D-
mannopyranoside, with the challenging UPEC strain at the time of inoculation (89-91). A 
knockout mutant UPEC strain deficient in FimH production due to a targeted deletion of 
the fimH gene, failed to bind human and mouse bladder epithelial tissues, a phenotype 
that could be restored by complementing fimH expression off a plasmid (92). The 
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discovery that cystitis could potentially be prevented or treated through disrupting type 1 
fimbria-mediated UPEC adherence to bladder epithelium, either pharmacologically or 
with host-generated antibodies, galvanized efforts to develop FimH-based vaccine 
designs. Indeed, mice immunized with FimHt, a mannose-binding truncated form of 
FimH, or a complex containing the periplasmic chaperone FimC bound to the full-length 
FimH protein, termed FimCH, were significantly protected from experimental UPEC 
infection in the bladder, exhibiting a 100- to 1000-fold reduction in the number of 
colonizing bacteria in comparison to adjuvant-only immunized controls (92). 
Immunization with the FimHt vaccine was able to generate a substantial and long-lasting 
humoral immune response as immunized mice had significantly higher levels of FimH-
specific urinary IgG, an outcome that correlated with the levels of protection from 
infection in the bladder (92). Cynomolgus monkeys immunized with the FimCH vaccine 
elicited a strong systemic humoral response and three out of four were protected from 
experimental UTI 48 hours post inoculation, in comparison with zero out of four 
monkeys in the adjuvant-only control group (93, 94).  
In 1999, the Maryland-based biotechnology company MedImmune, Inc. brought 
the UPEC type 1 fimbria subunit vaccine, FimCH, to phase II clinical trials with women 
volunteers. Unfortunately, MedImmune formally announced in early 2003 the 
discontinuation of further research and development of the FimCH vaccine, citing that 
the previous clinical trials failed to demonstrate a sufficient level of efficacy in 
prevention of UTIs to warrant additional larger Phase-III studies (95-97). Since the data 
from the FimCH Phase II clinical trials has not been published, the level of efficacy of 
the FimCH vaccine in humans remains unclear. In the decade since the start of FimCH 
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clinical trials, additional research on UPEC type 1 fimbriae has further complicated our 
understanding of its role during human infection. Microarray and transcriptional analysis 
data from women with active UTI suggest that genes encoding type 1 fimbrial subunits 
may not be highly expressed during UPEC infection of the human urinary tract (42, 98). 
In addition, the expression of type 1 fimbriae is phase variable, as its promoter region 
resides on an invertible element that switches fim expression between ON and OFF (99, 
100). Variation in type 1 fimbriae expression may allow invading UPEC to avoid 
detection from an adaptive immune response targeting this organelle. Lastly, recent 
evidence suggests that antibodies generated against the adhesive tip of type 1 fimbriae, 
FimH, do not target the mannose binding pocket or block FimH adhesion, may actually 
enhance the binding affinity of FimH for mannose, and are shed as mannose-bound FimH 
undergoes a conformational shift during binding (101). While these results may be at 
odds with our previous understanding of FimH-mediated vaccine protection, they may 
suggest an alternative explanation for FimH-based vaccine efficacy in mice.  The recent 
evidence suggesting UPEC gene expression may be different between mouse and human 
infection, and the experience with the FimCH vaccine, highlights our need to better 
understand UPEC antigen expression in the human host. Although the mouse model of 
ascending UTI is a valuable resource for testing vaccine efficacy and design, our ability 
to choose promising UPEC vaccine candidates would benefit enormously from having a 
more complete understanding of UPEC virulence gene expression during UTIs in 
humans.  
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Toxins. 
Vaccines containing inactivated bacterial toxins, termed toxoids, have been 
effective against a select number of bacterial pathogens and many of our current routine 
childhood vaccinations are toxoid-based, including the diphtheria, tetanus and acellular 
pertussis vaccine (DTaP) that contains both diphtheria and tetanus toxoids (56). UPEC 
genomes frequently contain genes that encode toxins including α-hemolysin (HlyA), 
cytotoxin necrotizing factor 1 (CNF1), cytolethal distending toxin (CdtB), and secreted 
autotransporter toxins Sat, Pic, and Tsh (103). Many of these toxins have been associated 
with symptom severity during urinary tract infection, such as increased inflammation, 
bladder epithelial cell shedding, and renal damage, but none have been shown to be 
required for infection and thus may represent less than ideal vaccine candidates (104, 
105). When the pore forming cytolytic toxin, α-hemolysin, was administered 
intramuscularly to mice, which were then challenged with an intravesicular injection of 
UPEC, no significant protection was acquired (102). It was noted, however, that the 
HlyA-immunized mice did suffer significantly less renal damage than their PBS-
immunized counterparts and although, toxoid-based vaccines may not be applicable for 
reducing the incidence of UTI, they may be effective at reducing infection severity in 
certain high-risk patient populations (Table 1-5).  
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Iron acquisition systems. 
 Nearly all forms of life require iron. Iron is an essential cofactor for enzymes 
involved in primary and secondary cellular metabolism, and a critical component of 
normal cell physiology. UPECs ability to colonize the host urinary tract is dependent on 
iron acquisition (107). Although the human body contains substantial iron, the majority is 
inaccessible to invading microorganisms as it is bound to the oxygen-carrying heme 
group within hemoglobin or sequestered by iron storage molecules such as ferritin and 
hemosiderin. The scarcity of free iron in the host is a major obstacle for microbial growth 
and the ability to circumvent this barrier is a hallmark of many successful bacterial 
pathogens (108).  
 UPEC survives in the iron-limited host urinary tract by upregulating the 
expression of molecular iron acquisition systems that synthesize and secrete small 
organic iron-chelating molecules called siderophores (42, 109). Siderophores have 
extremely high affinity for ferric iron and can successfully compete with host proteins for 
iron resources. Once iron is complexed, the ferri-siderophore is imported back into the 
bacterial cell through their respective outer membrane receptors, thereby allowing iron to 
be extracted from the host and used by the bacterium for its survival (110). In addition to 
expressing outer membrane iron receptors specific for its own siderophores, UPEC 
opportunistically expresses outer membrane receptors for iron-containing host molecules, 
such as heme, and the siderophores of other microorganisms, such as the fungal 
siderophore, ferrichrome (Figure 1-3).  
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Figure 1-3. Classes of UPEC outer membrane iron receptors. A cartoon depicting the 
various classes of β-barrel outer membrane iron receptors used by UPEC strains. These 
include: exogenous siderophore receptors that import siderophores synthesized by 
microorganisims other than UPEC (blue), endogenous siderophore receptors that import 
UPEC-synthesized siderophores (orange), and heme receptors (red).  
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In contrast to most commensal E. coli strains that encode few iron-acquisition 
systems, UPEC expresses a large arsenal of iron-acquisition systems (111). For example, 
the genome of prototypical pyelonephritis UPEC strain CFT073 encodes 14 characterized 
outer membrane iron compound receptors, as well as the biosynthesis machinery for three 
different siderophores: catecholates enterobactin and salmochelin, and the hydroxamate 
aerobactin (12). Many outer membrane iron compound receptors share the characteristics 
of an ideal UPEC vaccine target: 1) they are surface-exposed on the bacterium, 2) 
expressed during infection, and 3) prevalent among pathogenic E. coli strains. Thus far, 
seven UPEC outer membrane iron compound receptors (IroN, IreA, IutA, FyuA, Iha, 
Hma, and ChuA) have been evaluated as vaccine candidates to prevent UTI, five of 
which (IroN, IreA, IutA, FyuA, and Hma) significantly protect in a mouse model of 
infection, demonstrating that outer membrane iron receptors are a promising new class of 
UPEC vaccine targets (Table 1-6) (32, 112, 113).  
 Of the four possible siderophores produced by E. coli clinical isolates, three are 
more often produced by pathogens: aerobactin, yersiniabactin, and salmochelin (111, 
114). As a result, the outer membrane receptors for these siderophores have been 
investigated as prospective targets for vaccination. Subcutaneous immunization with a 
denatured form of the UPEC salmochelin outer membrane receptor, IroN, conferred 
significant protection from experimental UPEC infection in mouse kidneys and produced 
a significant IroN-specific serum IgG response (112). However, IroN immunization did 
not induce a significant systemic or mucosal IgA response or protect from experimental 
infection in the bladder, an outcome that could possibly be improved upon through the 
use of an adjuvant or alternative route of vaccine administration. Intranasal immunization 
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with the aerobactin receptor, IutA, conjugated to cholera toxin as adjuvant, significantly 
protected mice from experimental UPEC infection in both the bladder and kidneys, and 
induced a significant increase in IutA-specific urinary IgA (32). Although aerobactin 
production is pathogen-associated, gene expression data using mRNA isolated directly 
from bacteria in urine of women with active UTIs suggest that aerobactin production may 
not be widely abundant among UPEC strains, limiting the usefulness of an IutA-based 
UPEC vaccine (42). Subcutaneous immunization with the UPEC yersiniabactin receptor, 
FyuA, combined with Freund’s adjuvant, significantly protected mice from death in a 
lethal sepsis model of pathogenic E. coli infection (113). Passive immunization with 
purified sera from FyuA-immunized rabbits demonstrated the protection to be 
immunoglobulin-mediated. 
  In addition to the outer membrane receptors that facilitate ferrisiderophore 
import, UPEC vaccines have also targeted bacterial outer membrane receptors for host 
heme, the iron containing prosthetic group of hemoglobin and other hemoproteins. 
Intranasal immunization with the heme receptor Hma conjugated to cholera toxin as 
adjuvant, significantly protected mice from experimental infection with UPEC in the 
kidney, but not the bladder (32). Surprisingly, immunization with an alternative UPEC 
heme receptor, ChuA, did not provide significant protection from experimental infection 
(32, 113). 
Although iron acquisition is required for UPEC colonization of the host urinary 
tract, no single essential iron acquisition system has yet to be identified. Indeed, many 
UPEC iron acquisition systems may be functionally redundant and unequally expressed 
among UPEC strains, requiring a successful iron receptor-based UTI vaccine to target 
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more than one iron acquisition system to be broadly effective (42, 115, 116). 
Multiepitope vaccines that contain domains from many outer membrane iron receptors 
address this dilemma by generating protective immunity against several UPEC iron 
acquisition systems (Table 1-7). Recently, Wieser and colleagues (117) constructed two 
such multiepitope subunit vaccines (designated Vol1 and Vol2) containing domains from 
six E. coli outer membrane iron receptors (FyuA, IroN, ChuA, IreA, IutA and Iha) and 
the uropathogenic-specific protein (Usp) connected by spacer domains on single 
recombinant proteins. Intranasal immunization of mice with either Vol1 or Vol2, 
conjugated to cholera toxin as adjuvant, was able to significantly reduce UPEC bacterial 
loads in the liver 48 hours after experimental intraperitoneal UPEC challenge (117). 
However, only immunization with the Vol1 construct, containing domains from FyuA, 
IutA, Iha, and Usp, was able to significantly decrease experimental UPEC bacterial loads 
in the spleen (117). Similar results were obtained when the multiepitope vaccines were 
administered via a live bacterial antigen delivery system based on the Salmonella Type-
III secretion system (118). In agreement with earlier results, immunization with the Vol1 
(pST1) construct significantly reduced bacterial loads in the murine liver and spleen, in 
contrast to the Vol2 (pST2) that did not induce significant protection (118). These data 
from the multiepitope and iron receptor-based immunization studies are encouraging for 
UTI vaccine development and continued research into UPEC iron acquisition during 
infection may help inform future vaccine designs that target UPEC, as well as other 
pathogens that depend on iron acquisition to survive within the host.  
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Challenges to UPEC vaccine design. 
Strain diversity.  
While select individual antigen-based UPEC vaccines may successfully prevent 
experimental infection in animal models, a broadly effective UTI vaccine may need to 
target more than one virulence factor to be clinically useful against the highly 
heterogeneous UPEC population. Substantial diversity exists within classes of UPEC 
virulence factors, such that, not every UPEC strain expresses the exact same set of 
virulence-associated genes during infection (42). Although the genomes of pathogenic E. 
coli frequently encode many more virulence factors than commensal E. coli strains, the 
absence of a required core set of virulence factors complicates UTI vaccine design (12, 
78). Targeting a single virulence factor may only be effective against a select group of 
UPEC strains. Vaccine strategies that target multiple virulence factors, like the 
multiepitope vaccines constructed by Wieser and coworkers (117), provide a solution to 
the problem of UPEC strain diversity. Through targeting multiple members of a class of 
virulence factors, such as multiple fimbrial adhesins, or multiple iron receptors, rather 
than an individual, it may be possible to overcome UPEC diversity and design a clinically 
effective vaccine for UTI. 
Renal immunology and UPEC pathogenesis is poorly understood. 
In addition to tackling the ongoing challenge presented by UPEC strain diversity, 
UTI vaccine development could be better guided through further understanding UPEC 
pathogenesis and the host mucosal immune response to infection. It is still unclear why 
we are unable to generate an effective adaptive immune response after an initial UPEC 
infection, leaving us susceptible to repeat infection with the same UPEC strain. Future 
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UTI vaccine development strategies may need to include considerations for mechanisms 
by which UPEC may be impeding the host’s generation or implementation of a protective 
adaptive immune response. Mechanisms by which UPEC may be subverting the host 
immune response include interference with Toll-like receptor signaling, the formation of 
intracellular bacterial communities, the suppression of cytokine secretion, impedance of 
antibody binding, and reduction of the secretion of secretory IgA (27, 45, 120-122). 
Understanding UPEC immune modulating mechanisms could help guide strategies to 
combat repeat infection. In addition, better understanding the mucosal immune response 
to infection could provide guidance to more effective vaccine delivery systems and 
adjuvants. Defining what specific factors influence the robustness and longevity of a 
mucosal immune response in the urinary tract would allow vaccine delivery systems and 
adjuvants to be tailored more effectively. The development of novel adjuvants to improve 
the mucosal immune response to vaccines, as well as increasing our knowledge of how 
UPEC interacts with the host immune system could help inform rational UTI vaccine 
design. 
 
Shift towards a targeted approach to vaccine design. 
As well as further exploring the potential of already identified promising vaccine 
candidates; novel vaccine candidate discovery screens are helping to identify previously 
unrecognized UTI vaccine targets. Vaxign, a web-based vaccine design program 
developed by He and colleagues (123), was used to predict new UPEC vaccine targets 
based on a reverse vaccinology strategy. In addition to Vaxign, other discovery screens 
have been employed to identify novel vaccine targets. In a “subtractive reverse 
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vaccinology screen” by Moriel and coworkers (106), vaccine antigens were predicted 
using a bioinformatic analysis of three ExPEC strains (CFT073, 536, IHE3034). Antigens 
from CFT073, 536 and IHE3034 predicted to be surface associated or secreted, with three 
or fewer transmembrane domains were selected and compared against non-pathogenic E. 
coli strains (MG1655, DH10B, W3110) for exclusion. By this approach, 230 potential 
antigens were identified and tested in a mouse model of sepsis, nine of which were newly 
identified and found to protect against experimental ExPEC infection (Table 1-8) (106). 
Despite ongoing challenges, the progress towards discovering and testing novel vaccine 
candidates, adjuvants and delivery methods is promising and we are hopeful for the 
future development of a vaccine to prevent UTI. 
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CHAPTER 2 
IMMUNIZATION WITH THE YERSINIABACTIN RECEPTOR, FYUA, 
PROTECTS AGAINST PYELONEPHRITIS 
 
 
Author’s Note: This chapter is a modified version of the previously published research article: 
Brumbaugh AR, Smith SN and Mobley HLT. Immunization with the Yersiniabactin Receptor, 
FyuA, Protects Against Pyelonephritis in a Murine Model of Urinary Tract Infection. 2013. Infect 
Immun 81:3309-3316 
 
Abstract 
 Urinary tract infections (UTI) are common and represent a substantial economic 
and public health burden. Roughly 80% of these infections are caused by a heterogeneous 
group of uropathogenic Escherichia coli (UPEC) strains. Antibiotics are standard therapy 
for UTI, but a rise in antibiotic resistance has complicated treatment, making the 
development of a UTI vaccine more urgent. Iron receptors are a promising new class of 
vaccine targets for UTI as UPEC require iron to colonize the iron-limited host urinary 
tract, and genes encoding iron acquisition systems are highly expressed during infection. 
Previously, three of six UPEC siderophore and heme receptors were identified as vaccine 
candidates by intranasal immunization in a murine model of ascending UTI. To complete 
the assessment of iron receptors as vaccine candidates, an additional six UPEC iron 
receptors were evaluated. Of the six vaccine candidates tested in this study (FyuA, FitA, 
IroN, the gene product of the CFT073 locus c0294, and two truncated derivatives of 
ChuA), only FyuA provided significant protection (p = 0.0018) against UPEC 
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colonization. Intranasal immunization induced a robust and long-lived humoral immune 
response. In addition levels of FyuA-specific serum IgG correlated with bacterial loads in 
the kidneys (ρ(14) = -0.72, p = 0.0018), providing a surrogate of protection. FyuA is the 
fourth UPEC iron receptor to be identified from our screens, in addition to IutA, Hma and 
IreA, which were previously demonstrated to elicit protection against UPEC challenge. 
Together, these iron receptor antigens will facilitate the development of a broadly 
protective, multivalent UTI vaccine to effectively target diverse strains of UPEC.  
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Introduction 
The human urinary tract is one of the most common sites for bacterial infection, 
second only to the respiratory tract (124). Most urinary tract infections (UTI) are caused 
when pathogenic bacteria, commonly found in the gastrointestinal tract, colonize the 
perineum and traverse the urethra to cause an infection in the bladder, clinically termed 
cystitis. Left untreated, cystitis can progress to pyelonephritis as colonizing bacteria 
ascend the ureters to cause a secondary infection in the kidneys (6). In severe cases, 
invading bacteria can breach epithelial and endothelial barriers in the kidney to gain 
access to the bloodstream leading to systemic infection and sepsis, a serious and 
sometimes fatal complication (7).  
While most UTIs seldom cause life-threatening or long-term health problems, the 
regularity at which they occur generates a substantial economic and public health burden 
(125). An estimated half of all women and 12% of men will experience a UTI in their 
lifetime and almost a quarter of women who have one UTI will experience a second 
within 6-12 months (2). Commonly these infections become recurrent, with an estimated 
three percent of women suffering from very frequent and often constant UTI (3). At the 
community level, frequent UTIs tax healthcare and financial resources, requiring over 
five million physician office visits, two million emergency room visits (126), and 
500,000 hospitalizations annually in the United States (127), with associated annual costs 
estimated at $3.5 billion (5).  
To prevent more serious infection and speed recovery, patients with UTI are 
generally treated with a course of antibiotics, and individuals with recurrent infection 
may be prescribed antibiotics prophylactically (14). However, uropathogen resistance 
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rates to first- and second-line antibiotic therapies are steadily climbing, which can 
complicate treatment and lead to therapeutic failure (15-17). For example, the resistance 
rate of community-acquired UTI isolates to the first-line antibiotic trimethoprim–
sulfamethoxazole (TMP–SMX) currently exceeds 20% in most areas (15). Likewise, 
between 6-11% of community-acquired UTI isolates are resistant to the second-line 
fluoroquinolone agents, ciprofloxacin and levofloxacin (128-130), and alarmingly, 
roughly 25% of catheter-associated UTIs are fluoroquinolone-resistant (131). Multidrug 
resistance is also on the rise, so that now over 10% of cystitis isolates are resistant to at 
least three different classes of antimicrobial agents (22). Together, frequent and recurrent 
infection along with rising rates of antimicrobial resistance compromise effective long-
term treatment for UTI, making the development of alternative management therapies for 
UTI essential. 
Vaccine development represents a rational alternative approach to UTI 
prevention, where the most common cause of UTI, uropathogenic Escherichia coli 
(UPEC), can be specifically targeted (132-134). UPEC represent a heterogeneous group 
of extraintestinal pathogenic E. coli strains that are responsible for roughly 75-80% of all 
uncomplicated, or community-acquired UTIs (1) and an estimated 60% of complicated 
UTIs (135), or UTIs that occur in individuals where natural barriers to infection have 
been eroded by underlying conditions such as pregnancy or catheterization. Although 
UPEC strains can reside in the human gastrointestinal tract without causing disease, once 
in the urinary tract they use an arsenal of virulence factors to colonize and survive in this 
alternative ecological niche, inducing a robust inflammatory immune response (52). 
While certain virulence factors can be more prevalent among UPEC strains, as of yet, no 
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core set of virulence factors required for UPEC to cause UTI have been determined, 
making the identification of optimal UPEC vaccine targets a challenge (57).  
Given that conventional vaccinology approaches targeting established UPEC 
virulence factors have yet to produce a commercially available vaccine for UTI, we 
undertook an alternative and unbiased, functional vaccinology approach to vaccine 
discovery that has been employed successfully against other bacterial pathogens such as 
Streptococcus pneumoniae (136), Salmonella (137) and Neisseria meningitidis (138). By 
analyzing data compiled from a series of genomic (109, 139-141), proteomic (142-145) 
and metabolic (111) screens, we were able to select UPEC antigens that fit criteria 
hypothesized to be desirable in a vaccine antigen, which we describe as PASivE: 
Pathogen-specific, Antigenic, Surface-exposed, and in vivo Expressed (34). Screening 
vaccine antigens for PASivE criteria ensured that the vaccine targets selected would not 
be expressed by commensal E. coli, would be accessible to and recognized by the host 
immune system, and be highly expressed and likely important for UPEC pathogenesis 
during UTI. Of the 5379 predicted proteins encoded by the prototype pyelonephritic 
UPEC strain CFT073, only six proteins, all involved in iron acquisition met the rigorous 
PASivE criteria (146).  
Of the vaccine candidates identified using PASivE criteria, three (Hma, IutA, 
IreA) were found to protect against experimental UTI, establishing outer membrane iron 
receptors as a practical class of UPEC vaccine antigens (146). The purpose of this study 
was to complete the characterization of iron receptors as vaccine antigens by evaluating 
an additional six UPEC outer membrane iron receptors. Here, we describe the 
identification of the yersiniabactin receptor, FyuA, as a protective antigen that elicits a 
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sustained and robust serum IgG response following intranasal vaccination that correlates 
with the protection of mice transurethrally challenged with UPEC.  
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Materials and methods 
 
Bacterial strains and culture conditions.   
E. coli strains used in this study were cultured in Luria broth (10 g/l tryptone, 5 g/l 
yeast extract, 0.5 g/l NaCl) at 37°C with aeration. E. coli strain 536 was isolated from a 
patient suffering from urinary tract infection (147) and E. coli strain CFT073 was isolated 
from the blood and urine of a hospitalized patient with acute pyelonephritis (148).  
 
Plasmid Construction.  
Genes encoding candidate vaccine antigens were PCR-amplified from E. coli 
CFT073 genomic DNA (c0294, fitA, iroN chuA.m, chuA.c) or 536 genomic DNA (fyuA) 
using the primers listed in Table 2-1 and cloned into the XhoI and HindIII restriction sites 
of pBAD-myc-HisA (Invitrogen) to produce C-terminal tagged myc-His6X fusions. The 
resulting constructs were verified by sequencing.  
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Vaccine Antigen Preparation.  
Recombinant protein expression was induced in E. coli TOP10 (FyuA-His6x, 
c0294-His6x, ChuA.c-His6x), E. coli BL21 (ChuA.m-His6x), or E. coli C41(DE3) (IroN-
His6x, FitA-His6x), cultured in Terrific broth (12 g/l tryptone, 24 g/l yeast extract, 4 ml/l 
glycerol, 100 ml/l filter sterilized 0.17 M KH2PO4 and 0.72 M K2HPO4) at 37°C with 
aeration to an OD600 = 0.5-1.0 by the addition of 1 mM L-arabinose. Induced cultures 
were incubated at 37°C with aeration for 4 h before being harvested by centrifugation 
(8,000×g, 10 min, 4°C). 
Bacterial pellets were resuspended in 10 mM HEPES, pH 7, and 100 U 
Benzonase nuclease (Sigma-Aldrich). Bacterial suspensions were lysed by two passages 
through a French pressure cell (20,000 psi) and the lysate was cleared by centrifugation 
(8,000×g, 10 min, 4°C). Bacterial membranes and insoluble aggregates were separated 
from the cleared lysate by ultracentrifugation (112,000×g, 30 min, 4°C) and solubilized 
in 5 ml 100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, 1% ASB-14, pH 8.0. His-tagged 
proteins were purified by affinity chromatography, using nickel-nitriloacetic acid agarose 
(Qiagen) under denaturing conditions according to the manufacturer’s instructions (The 
QIAexpressionist). Eluted protein was renatured by four successive dialysis steps at 4°C 
(dialysis buffer 1: 100 mM NaH2PO4, 5 mM Tris, 6 M Urea, 50 mM NaCl, pH 5.5; 
dialysis buffer 2: 100 mM NaH2PO4, 2.5 mM Tris, 4 M Urea, 100 mM NaCl, 0.005% 
Zwittergent, pH 6.5; dialysis buffer 3: 100 mM NaH2PO4, 2 M Urea, 150 mM NaCl, 
0.01% Zwittergent, pH 7.4) into a final solution containing 0.05% Zwittergent in PBS, 
pH 7.4 and quantified using the BCA protein assay (Pierce).  
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Vaccination.  
Purified antigens were chemically cross-linked to cholera toxin (CT) (Sigma-
Aldrich) at a ratio of 10:1 using N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) 
(Pierce) according to the manufacturer’s recommendations. Cross-linked antigens were 
administered to six- to eight-week-old female CBA/J mice intranasally 20 µl/mouse (10 
µl/nare). Animals received a primary dose on day 0 of 100 µg antigen cross-linked to 10 
µg CT or 10 µg CT alone. Two booster immunizations of 25 µg antigen cross-linked to 
2.5 µg CT or 2.5 µg CT alone were administered on days 7 and 14. When appropriate, 
mice were transurethrally challenged with a UPEC strain on day 21 as described below 
for the murine model of ascending UTI. 
 
Murine model of ascending UTI.   
Female CBA/J mice were inoculated transurethrally as previously described 
(149), with modification. Bacteria were cultured overnight in LB at 37°C with aeration. 
The inoculating strain was harvested by centrifugation (3500×g, 30 min, 4°C) and 
resuspended in PBS to OD600 ≈ 4.0 (~1 x 109 CFU/ml) and 50 µl of this suspension (108 
CFU) was delivered to each mouse via a sterile 0.28 mm polyethylene catheter attached 
to an infusion pump (Harvard Apparatus) with a flow rate of 100 µl/min. The inoculum 
was quantified by plating dilutions onto LB agar.  Forty-eight hours post-inoculation 
(hpi), organs were removed from euthanized mice and homogenized in 3 ml PBS using a 
GLH homogenizer (Omni International).  Using an Autoplate 4000 spiral plater (Spiral 
Biotech), tissue homogenates were plated onto LB agar.  Colonies were enumerated with 
a QCount automated plate counter (Spiral Biotech) and CFU/g tissue determined 
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(output). Protocols involving CBA/J mice complied with all relevant federal guidelines 
and institutional policies.  
 
ELISA.  
For the indirect enzyme-linked immunosorbent (ELISA) assay, 50 µl of 10 µg/ml 
purified protein diluted in carbonate buffer (100 mM, pH 9.6) was coated onto 96-well 
EIA/RIA high-binding polystyrene plates (Corning, Costar #9018) and incubated at 4°C 
overnight. Plates were washed by flooding all wells three times with wash buffer (0.05% 
Tween 20 in PBS) using an ELx405 (Bio-Tek Instruments, Inc.) Microplate Washer. 
Non-specific binding sites were blocked with SuperBlock blocking buffer (Pierce) as 
recommended by the manufacturer and the plates were washed with wash buffer. Wells 
were coated with serum diluted 1:250 in blocking buffer or 50 µl undiluted urine and 
allowed to incubate for 1 h at 23°C. Plates were washed with wash buffer and coated with 
the secondary antibody, goat anti-mouse IgG (Abcam ab97265), or goat anti-mouse IgA 
(Abcam ab97235) diluted 1:10,000 in blocking buffer and allowed to incubate a 23°C for 
1 h. Plates were washed and 50 µl of substrate, 1-Step Ultra TMB-ELISA (Thermo 
Scientific, 34018) was added and allowed to incubate at 23°C until color developed (≤20 
min). Reactions were stopped by the addition of sulfuric acid and the absorbance of each 
well was read with a µQuant plate reader (Bio-Tek Instruments, Inc.) at a wavelength of 
450 nm. 
 
 50 
Statistical analyses.   
Graphing and statistical analyses were performed using Prism® version 6 
(GraphPad Software, Inc.) and R version 2.14.1 (R Development Core Team, 2011) 
(150). Significance was determined using a one- or two-tailed Mann-Whitney test where 
appropriate and correlates of protection were determined using a two-tailed Spearman’s 
rank test with linear regression to generate a best-fit line. Outliers as determined to be three 
times the interquartile range by boxplot analysis were removed. All statistics were 
conducted using 95% confidence intervals where applicable.  
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Results 
 
Candidate antigen expression and purification.  
In preparation for immunization, the genes for six vaccine antigens, FyuA, IroN, 
c0294, FitA, ChuA (M) (middle fragment of ChuA; amino acid residues 260-493), and 
ChuA (C) (C terminal fragment of ChuA; amino acid residues 494-660) were cloned as 
His6X translational fusions, expressed, and purified under denaturing conditions as His6X 
affinity-tagged recombinant proteins. Bacterial cultures expressing recombinant vaccine 
antigens were lysed and bacterial membrane proteins were harvested by 
ultracentrifugation. The pelleted membrane proteins were solubilized in 8 M urea and 
passed over a nickel-affinity column to enrich for vaccine antigen. Fractions with 
concentrated vaccine antigen were pooled and visualized by SDS-PAGE (Figure 2-1). 
Urea was removed stepwise to allow outer membrane iron receptor vaccine antigens to 
refold by a series of dialysis steps to regain a beta barrel configuration as has been 
demonstrated by circular dichroism (146).  
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Figure 2-1. Expression and purification of UPEC outer membrane iron receptors. 
Genes encoding outer membrane iron receptors were cloned from UPEC strains 536 and 
CFT073. Iron receptors were recombinantly expressed with a His-tag and purified using 
immobilized nickel affinity chromatography. Purified protein fractions were separated by 
SDS-PAGE and stained with Invitrogen SimplyBlue™ SafeStain. Predicted size of 
tagged FyuA, 77 kDa; IroN, 83 kDa; c0294, 82 kDa; FitA, 82 kDa, (ChuA Middle 
fragment) ChuA (M), 30 kDa; (ChuA C Terminal fragment) ChuA (C), 22 kDa. Circle 
(!) and diamond (") symbols indicate the location of the 75 kDa and 37 kDa standard 
bands respectively for each individual gel.   
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Immunization with FyuA confers protection against pyelonephritis.  
To induce a robust mucosal immune response, purified vaccine antigens were 
biochemically cross-linked to cholera toxin (CT) as adjuvant, at a ratio of (10:1) 
(antigen:CT). Mice were immunized intranasally with either adjuvant-conjugated vaccine 
antigen (antigen:CT) or adjuvant alone (CT). Following primary immunization with 100 
µg antigen cross-linked to 10 µg CT or 10 µg CT alone (day 0) and two booster doses of 
25 µg antigen cross-linked to 2.5 µg CT or 2.5 µg CT alone (days 7 and 14), mice were 
transurethrally inoculated on day 21 with 1 x 108 colony forming units (CFU) of UPEC. 
The prototypical pyelonephritis strain CFT073 was used as the challenge strain in all 
experiments, except when evaluating the vaccine antigen FyuA, where UPEC strain 536 
was substituted as CFT073 does not express the siderophore receptor FyuA. The 
infection was allowed to progress for 48 hours before the mice were euthanized and their 
bladders and kidneys removed. Organs were homogenized and the UPEC bacterial load 
in the infected organs was quantified by determination of CFU (Figure 2-2). Of the six 
outer membrane iron receptor vaccine formulations tested, only the FyuA-based vaccine 
significantly protected (p = 0.0018) against experimental UTI, with vaccinated mice 
having a 29-fold decrease in median levels of UPEC kidney colonization in comparison 
to mice that only received adjuvant (Figures 2-2A). While data for FyuA are pooled in 
Figure 2-2A, vaccination with the antigen and control (CT alone) had been carried out in 
three independent trials. In each case, FyuA-vaccinated mice had at least a 12-fold 
reduction (12.92, 95.65, and 14.18) in the median level of UPEC kidney colonization in 
comparison to mice given only adjuvant with one of the three reductions being 
statistically significant (p = 0.2575, p = 0.0861, p = 0.0090). Although mice immunized 
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with the IroN- and FitA-based vaccines also had reduced median levels of UPEC kidney 
colonization, neither reduction was statistically significant (p = 0.270 and p = 0.188, 
respectively) (Figures 2-2B, D).  
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Figure 2-2. Immunization with the yersiniabactin receptor FyuA protects against 
experimental pyelonephritis. Female CBA/J mice were intranasally vaccinated as described 
with a primary dose of 100 µg purified protein crosslinked to 10 µg CT followed by two 
boosts of 25 µg antigen crosslinked to 2.5 µg CT. One week following the final boost, 
animals were transurethrally inoculated with 1×108 CFU of E. coli 536 (A) or CFT073 (B-F) 
and colonization was measured 48 hpi. Animals per group (A) CT: n = 30 FyuA: n = 29 in 
three independent immunization experiments (Kidneys P = 0.0430, 0.0045, 0.1287), (B) CT: 
n = 10 IroN: n = 9 in a single immunization experiment, (C) CT: n = 20 c0294: n = 20 in two 
immunization experiments, (D) CT: n = 20 FitA: n = 20 in two immunization experiments, 
(E) CT: n = 10 ChuA.m: n = 10 in a single immunization experiment, (F) CT: n = 20 
ChuA.c: n = 20 in two immunization experiments. Symbols represent CFU/g tissue or /ml 
urine of individual mice and bars indicate median values. Dashed line shows the limit of 
detection for this assay, 100 CFU/g. Significance was determined using a two-tailed Mann-
Whitney test. Only statistically significant differences are noted. 
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Immunized mice produce vaccine-specific serum IgG.  
To verify that intranasal immunization with UPEC iron receptor-based vaccines 
induces a vaccine-specific humoral immune response, serum samples were taken from 
each mouse prior to the primary immunization (day 0) and again before UPEC challenge 
(day 21). The levels of vaccine antigen-specific serum IgG were quantified via indirect 
ELISA (Figure 2-3). All vaccine formulations induced a robust, antigen-specific serum 
IgG response following intranasal immunization, confirming that the failure of some 
vaccine antigens to significantly reduce median UPEC colonization levels was not due to 
the insufficient induction of a humoral immune response (Figures 2-3B-F). 
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Figure 2-3. Intranasal immunization with the yersiniabactin receptor FyuA and all 
other antigens induces significant antigen-specific serum IgG expression in mice. Serum 
was collected from antigen-CT immunized or CT (CT) immunized mice prior to 
immunization (Pre-Immunization) and after immunization, but before UPEC challenge (Post-
Immunization). Samples were plated in antigen-coated plates and probed for antigen-specific 
IgG via indirect ELISA. Absorbance reflects relative quantity of serum IgG. Each 
experimental group consists of 20 individual mice from two separate immunization 
experiments. Error bars indicate the mean +/- SD. Significance was determined using a one-
tailed Mann-Whitney test. 
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Immunized mice secrete vaccine-specific IgA in urine.  
To evaluate the humoral immune response at the site of UPEC colonization, urine 
samples were collected from individual mice following a course of immunization with 
either CT or FyuA-CT and the levels of FyuA-specific urinary IgA and IgG were 
quantified by indirect ELISA (Figures 2-4A, B). Intranasal immunization with the FyuA-
based vaccine induced statistically significant levels of urinary IgA and IgG in 
comparison to CT-immunized mice (Figures 2-4A, B). 
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Figure 2-4. Mice immunized intranasally with the yersiniabactin receptor FyuA 
produce FyuA-specific urinary antibodies. Urine collected from FyuA-CT immunized 
(FyuA) or CT (CT) immunized mice was plated on FyuA-coated plates and probed for 
FyuA-specific IgA (A) or IgG (B) antibodies via indirect ELISA. Absorbance reflects 
relative quantity of immunoglobin. Each group (CT) or (FyuA) consists of 10 individual 
mice from a single immunization experiment. Error bars indicate the mean +/- SD. 
Significance was determined using a one-tailed Mann-Whitney test.  
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Vaccine-specific serum antibodies correlate with UPEC bacterial load.  
 Almost all current vaccines block infection by inducing pathogen-specific 
antibodies in the serum or mucosa and if a serological correlate of protection can be 
identified from a humoral immune response, it can provide a valuable tool to evaluate 
vaccine efficacy and design (151). Given our hypothesis that vaccine-mediated protection 
against UTI is dependent on a robust humoral immune response, it was important to 
determine whether antibody levels in vaccinated mice correlated with UPEC bacterial 
load in the urinary tract following transurethral challenge. To evaluate whether we could 
identify a serological correlate of protection for any of the antigens, we performed a 
Spearman’s rank analysis comparing the levels of vaccine-specific serum IgG and the 
amount of UPEC bacterial load (CFU/g kidney) for each vaccine antigen using data from 
each vaccinated mouse (Figures 2-5A-F). Only in the group of mice immunized with the 
protective vaccine antigen, FyuA, did a reduction of UPEC bacterial colonization of the 
kidney strongly correlate with levels of vaccine-specific serum IgG (ρ(14) = -0.72, p = 
0.0018) (Figure 2-5A). Levels of FyuA-specific urinary IgA or serum IgG did not 
significantly correlate with UPEC bacterial load in the bladder (data not shown). 
 
  
 61 
 
 
Figure 2-5. Correlation between vaccine-specific serum IgG titer and reduced 
bacterial counts is observed only in mice immunized with the protective vaccine. 
Normalized kidney CFU values from immunized and E. coli challenged mice are plotted 
against their respective vaccine-specific serum IgG levels as measured by indirect ELISA, 
where absorbance at 450 nm reflects the relative quantity of vaccine-specific serum IgG. 
Dashed line indicates the limit of detection for the immunization assay, 100 CFU/g kidney 
tissue. Correlative significance was determined using a two-tailed Spearman’s rank 
correlation and the best-fit line was determined by linear regression; shown only when there 
is a statistically significant correlation (p < 0.05). Results of linear regression in (A) 
R2 = 0.60, F(1,14) = 20.6, p = 0.005. 
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Immunization with FyuA generates long-lived plasma cells.  
 Upon initial antigen exposure, naïve B cells can progress through two different 
paths of cell development, differentiating into either short- or long-lived plasma cells. 
Short-lived plasma cells mediate the initial humoral response to antigen by secreting 
large amounts of antibodies, and typically appear 3-6 days after immunization and 
disappear after two weeks through programed cell death (152). Naïve B cells that 
differentiate into long-lived plasma cells, move to the bone marrow after maturation and 
maintain serological memory by continuing to secrete antibodies long after initial 
infection, thereby providing a critical first-line of defense against reinfection (152). To 
determine if vaccination with UPEC iron receptors has the potential to provide long-term 
immunity through the generation of long-lived plasma cells, we monitored vaccine-
specific serum antibody levels for several weeks after immunization, to the point when 
serum antibody production could no longer be attributed to short-lived plasma cells. Per 
our defined dose and vaccination schedule we intranasally immunized five female CBA/J 
mice with CT-crosslinked FyuA and obtained weekly serum samples during the course of 
the immunization and for eight weeks following the last vaccine antigen booster dose. At 
the time when a transurethral challenge with UPEC would ordinarily be conducted, 
FyuA-specific serum IgG was at or near its highest level (Figure 2-6). Near peak levels of 
FyuA-specific serum antibodies were maintained for at least 70 days after initial 
vaccination and at least 56 days after the last booster dose (Figure 2-6). Given that the 
half-life for serum IgG subtypes averages 21 days or shorter, the sustained antibody 
response at 70 days in the absence of additional boosting suggests that immunization with 
FyuA generated FyuA-specific long-lived plasma cells. 
 63 
 
Figure 2-6. Immunization with the yersiniabactin receptor FyuA generates long-lived 
plasma cells. Five female CBA/J mice were intranasally vaccinated as described with a 
primary dose (P) of 100 µg purified FyuA crosslinked to 10 µg CT followed by two booster 
doses (B) of 25 µg FyuA crosslinked to 2.5 µg CT. Weekly serum samples were taken from 
mice (prior to same-day immunizations) and FyuA-specific serum IgG levels were quantified 
via indirect ELISA. The shaded area indicates the immunization period and arrows indicate 
when vaccine was administered. Dashed line indicates the time point when mice would 
ordinarily be challenged with UPEC to evaluate vaccine efficacy in a vaccine trial. 
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Discussion 
  UTIs are persistent in the general community and among hospitalized 
patients and, with rising rates of antibiotic resistance, are becoming increasingly more 
difficult to treat. The development of an effective UTI vaccine to lessen this substantial 
public health burden would be enormously beneficial to the population at large. 
Previously we identified iron acquisition proteins, including siderophore and heme 
receptors, as potent vaccine antigens that can protect the urinary tract from UPEC 
colonization. In a systematic screen, we tested six outer membrane components of 
distinct iron acquisition systems of E. coli CFT073 and identified three antigens that 
protect against infection (IreA, IutA, Hma) when used for intranasal vaccination (146). 
Having recognized iron acquisition proteins as a defined target for vaccination, here we 
described the evaluation of an additional six iron acquisition proteins for vaccination to 
prevent UTI.  
Of the six candidate antigens described here, only the yersiniabactin receptor, 
FyuA, stimulated a protective response, whereas IroN, FitA, ChuA fragments, and the 
gene product of CFT073 locus c0294 did not. FyuA-immunized mice elicited a vaccine-
specific humoral immune response that strongly correlated with levels of UPEC kidney 
colonization after transurethral challenge with 108 CFU of E. coli 536. This humoral 
response was maintained for at least eight weeks following final antigen exposure, 
providing evidence for the generation of long-lived, vaccine-specific plasma cells, and 
demonstrates that an FyuA-based vaccine has the potential to provide robust and long-
term protection against UTI. Not surprisingly, the other five antigens tested also elicited 
strong serum antibody responses following intranasal immunization; however, none 
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significantly protected from UPEC challenge or induced a correlative humoral immune 
response. Given the harsh denaturing conditions required for the purification of antigens, 
it is unlikely that the immune response we observe after immunization is the result of 
lipopolysaccharide (LPS) contamination in our vaccine preparations. When we tested our 
vaccine preparations previously we detected no contaminating LPS by limulus amebocyte 
lysis assay (146). In addition, given that five out of the six vaccine antigens failed to 
protect against infection, it is highly unlikely that the protection observed for one antigen 
could be the result of contaminating LPS.  
Why five of these antigens failed to provide protection despite inducing high 
levels of vaccine-specific antibodies is unclear. It is unlikely that all the vaccine targets 
are equally accessible by the host’s humoral immune system, and possible differences in 
the abundance or exposure of vaccine targets on the bacterial surface may offer an 
explanation for the observed differences in vaccine efficacy. In addition, although we 
hypothesize that bacterial clearance is mediated by pathogen opsonization or 
neutralization, another possible mechanism may be the generation of antibodies that bind 
to the receptors and inhibit their function. That is, a successful protective antigen might 
have to generate antibodies that both opsonize bacteria and fix complement as well as 
prevent the uptake of the cognate siderophore, in this case yersiniabactin. This hypothesis 
awaits testing for loss of function (iron uptake) studies in vaccinated mice. 
 Clearly, variations in mouse model, immunization route, adjuvant, antigen 
preparation and dose, challenge strain and inoculum dose, and challenge method all have 
an impact on the evaluation of vaccine efficacy. For example in previous studies, 
denatured IroN delivered subcutaneously with Complete Freund’s adjuvant to BALB/c 
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mice protected against lethal challenge with the extraintestinal pathogenic E. coli 
(ExPEC) strain S26 delivered intraperitoneally (113), or if administered without adjuvant, 
protected BALB/c mice from kidney colonization by ExPEC strain CP9 delivered 
intravenously (112). The candidate antigen FitA, when administered intraperitoneally 
with Complete Freund’s adjuvant or Incomplete Freund’s adjuvant to CD1 mice, 
protected against lethal challenge from ExPEC strains CFT073 and IH3034 delivered 
intraperitoneally, and ExPEC strain 536 delivered intravascularly (106). Such differences 
in experimental design between our studies and those of others may account for the 
differences we observe in protection for IroN and FitA antigens.  
During our previous UPEC vaccine antigen screen (146), we tested the potential 
of the vaccine antigen ChuA to protect against experimental UTI, but only 19 out of 30 
ChuA-immunized mice survived immunization. To more clearly evaluate the potential of 
ChuA as a UPEC vaccine candidate, we designed and evaluated truncated derivatives of 
ChuA. Although none of the mice immunized with truncated derivatives of ChuA 
experienced toxic effects during the course of immunization as we had observed for 
intact ChuA, neither truncated ChuA derivative (M or C) significantly protected mice 
from transurethral challenge. Although it is possible that individual immunogenic 
epitopes of ChuA could have been disrupted by expressing only fragments of the protein, 
the results presented here are in accordance with our previous study (146) using whole 
renatured ChuA and work done by Durant and colleagues evaluating denatured ChuA as 
an ExPEC vaccine antigen (113). 
The identification of FyuA as a protective vaccine antigen against UPEC adds a 
fourth antigen, in addition to Hma, IreA, and IutA identified previously (146), that can be 
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included in an intranasal vaccine to prevent UTI. Epidemiological studies and gene 
expression data indicate that fyuA is highly expressed during UTI in women (42), 
prevalent among UPEC strains, being carried on the High Pathogenicity Island (153, 
154), and an important fitness factor during experimental UTI (155). In addition, 
protection from infection after FyuA immunization has been demonstrated in alternative 
models of ExPEC infection. Subcutaneous immunization with denatured FyuA 
significantly protected BALB/c mice against lethal challenge by the ExPEC strain S26 
(113), and a multiepitope vaccine containing a fragment of FyuA protected mice from 
intraperitoneal challenge by CFT073 in the liver and spleen (117). Indeed, given that 
many bacterial pathogens require a source of iron to cause infection, FyuA is critical for 
the virulence of other enteric pathogens, such as Yersinia (156) and Klebsiella (157) 
species.  
Interestingly, immunization with FyuA provided protection in a tissue-specific 
manner, significantly reducing UPEC infection in the kidneys, but not in the bladder. 
Tissue-specific protection has been observed before for antigens Hma, which also only 
protected in the kidney, and IreA, which only protected in the bladder and provokes 
questions of the role of these iron receptors during infection and whether differences in 
iron receptor expression or function between organs sites may account for the observed 
differences in tissue-specific protection. In addition, although we found levels of FyuA-
specific serum IgG to be a surrogate of protection after immunization, it is still unclear 
whether the levels of FyuA-specific IgG mediates clearance of the urinary tract, or 
whether alternative mechanisms or components of the adaptive immune response are 
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providing UPEC clearance, such as urinary IgA or cellular immunity. These hypotheses 
await testing by passive protection and adoptive transfer assays in a mouse model of UTI. 
Clearly, targeting bacterial iron acquisition systems represents a rational approach to 
UPEC vaccine development. The four protective iron receptor vaccine antigens identified 
in our combined screens, Hma, IreA, IutA, (146) and FyuA described here, are highly 
expressed during infection and are more prevalent among uropathogenic strains, 69%, 
20%, 65%, and 87%, than fecal commensal strains, 17%, 17%, 17%, and 59%, 
respectfully (142, 158). Because no single antigen is present in all UPEC strains, and 
absent from all commensal strains, targeting a single iron receptor is unlikely to yield the 
broad level of immunity required for an effective UTI vaccine. However, by combining 
the identified antigens we can develop an iron receptor-based multi-epitope vaccine with 
the potential to provide broad protection against the heterogeneous UPEC population. 
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CHAPTER 3 
                      BLOCKING YERSINIABACTIN ATTENUATES 
PATHOGENIC ESCHERICHIA COLI IN CYSTITIS AND PYELONEPHRITIS 
AND IS A NOVEL THERAPEUTIC TARGET TO PREVENT  
URINARY TRACT INFECTION 
 
 
Author’s Note: This chapter is a modified version of the submitted research article: Brumbaugh 
AR, Smith SN, Subashchandrabose S, Himpsl SD, Hazen TH, Rasko DA and Mobley HLT. 
Blocking Yersiniabactin Attenuates Extraintestinal Pathogenic Escherichia coli in Cystitis and 
Pyelonephritis and is a Novel Therapeutic Target to Prevent Urinary Tract Infection.  
 
Abstract 
The emergence and spread of antibiotic resistance mechanisms such as extended-
spectrum beta-lactamases and carbapenemases among common bacterial pathogens is 
threatening our ability to treat routine hospital- and community-acquired infections, such 
as urinary tract infection (UTI) and pneumonia. With the pipeline for new antibacterial 
drugs for Gram-negative enteric bacteria virtually empty, there is an urgent need to 
develop new therapeutics. Bacteria require iron to establish infection and specialized 
pathogen-associated iron acquisition systems like yersiniabactin, common among highly 
pathogenic species in the family Enterobacteriaceae including Klebsiella pneumonia and 
Escherichia coli, are potentially novel therapeutic targets. Although the yersiniabactin 
receptor, FyuA, was recently identified as a protective vaccine target for E. coli UTI, the 
contribution of yersiniabactin to uropathogenic E. coli (UPEC) pathogenesis is unknown.  
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 Using an E. coli mutant unable to acquire yersiniabactin (536ΔfyuA) during 
infection, we established the yersiniabactin receptor as a UPEC virulence factor during 
cystitis and pyelonephritis, a fitness factor during bacteremia, and the surface-accessible 
target of the experimental FyuA vaccine. In addition, we determined through RNAseq 
analyses of RNA from E. coli causing cystitis in women that iron acquisition systems, 
including the yersiniabactin system, are highly expressed by bacteria during natural 
uncomplicated UTI. Yersiniabactin contributes to the virulence of several pathogenic 
species in the family Enterobacteriaceae, including UPEC, and its association with 
multidrug-resistance makes it a promising target to combat antibiotic resistant infections. 
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Introduction 
Widespread and increasing antibiotic resistance among bacterial pathogens that 
cause some of our most common healthcare-associated and community-acquired 
infections is jeopardizing our ability to prevent and treat routine infectious diseases (159). 
Two pathogens of particular concern are uropathogenic Escherichia coli (UPEC), which 
causes the majority (80%) of uncomplicated urinary tract infections (UTI) (9) and 
Klebsiella pneumoniae, a frequent cause of hospital-acquired pneumonia and UTI (160). 
Without adequate treatment, both UPEC and K. pneumoniae can breach epithelial and 
endothelial barriers to gain access to the bloodstream, causing life-threatening bacteremia 
(161). E. coli resistance rates to fluoroquinolones and 3rd generation cephalosporins now 
exceed 50% in 5 of 6 global regions, and similar resistance rates were reported for K. 
pneumoniae worldwide (162). Unfortunately, this means that the treatment of severe 
infections caused by these species must rely on carbapenems, the last-resort to treat 
severe community- and hospital-acquired infections (129). Not only are these 
antibacterials more expensive and less available in resource-constrained settings, but their 
extended use has contributed to the emergence of carbapenem-resistant 
Enterobacteriaceae (CRE), a serious global public health concern (163).  
Increasing rates of antimicrobial resistance and a lack of new therapeutics in the 
drug development pipeline has renewed interest in novel antibiotic discovery. We 
hypothesized that targeting nutrient acquisition in pathogenic bacteria, specifically 
systems that acquire iron, could provide a novel mechanism to prevent or treat infection. 
Iron is an essential cofactor for normal cell physiology and bacteria require a source of 
iron to establish infection (164). Most tissues in the body limit iron availability to 
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microorganisms, meaning that available ferrous iron is scarce, and most iron is 
sequestered in storage and carrier molecules such as transferrin, lactoferrin and ferritin, or 
bound to heme in hemoglobin and hemopexin (165). During infection, additional iron 
sequestration occurs as epithelial cells and neutrophils secrete lipocalin-2, a competitor 
for the bacterial iron-scavenging siderophore enterobactin, among others, and iron 
absorption and recycling pathways are repressed (166). Collectively these antimicrobial 
mechanisms are characterized as ‘nutritional immunity’ (167) and the ability to 
circumvent these barriers to iron acquisition is a hallmark of successful pathogens. 
Many pathogenic species in the family Enterobacteriaceae, including UPEC and 
K. pneumoniae, have multiple and often redundant iron acquisition systems to facilitate 
infection (115). The genome of UPEC strain 536, for example, encodes two heme 
receptors (Hma, ChuA), three siderophore systems (enterobactin, salmochelin, and 
yersiniabactin), and receptors for two fungal siderophores (FhuA, FhuE), as presented in 
Table 3-1 (168). Of particular interest is the yersiniabactin system, which is often 
pathogen-associated (158) and encoded on the high-pathogenicity island (HPI), a 
horizontally acquired 30 kb chromosomal region common among highly pathogenic 
strains of Yersinia pestis, Y. enterocolitica, Y. pseudotuberculosis, K. pneumoniae, K. 
oxytoca, Salmonella enterica and E. coli (169). Animal studies confirm that 
yersiniabactin contributes to the virulence of K. pneumoniae during respiratory infection 
(157), and of Y. pestis during bubonic and pneumonic plague (170). Recently, we 
identified the receptor for yersiniabactin, FyuA, as a protective vaccine target against E. 
coli-mediated pyelonephritis in a murine model of UTI (171). Although the 
yersiniabactin system is pathogen-associated, a protective vaccine target in the urinary 
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tract, and more prevalent among UPEC isolates that cause pyelonephritis (94%) and 
cystitis (87%) as compared to commensal E. coli strains (59%), the contribution of the 
yersiniabactin system to E. coli pathogenesis during UTI is unknown (57).   
The purpose of this study was to determine if the yersiniabactin system 
contributes to UPEC pathogenesis during UTI, and whether the yersiniabactin-mediated 
virulence is different between the kidney and bladder, which would clarify the kidney-
specific protection of the experimental FyuA vaccine. Understanding yersiniabactin-
mediated pathogenesis has the potential to provide a new therapeutic target for a number 
of highly pathogenic bacterial species that cause some of our most common community- 
and hospital-acquired infections. Here we describe the use of a yersiniabactin receptor 
mutant (ΔfyuA) to establish the yersiniabactin system as a UPEC virulence factor during 
cystitis and pyelonephritis, a fitness factor during bacteremia, and the surface-accessible 
target of the FyuA vaccine. In addition, we demonstrate through RNAseq analysis of 
RNA isolated directly from E. coli in urine from women with cystitis that iron acquisition 
systems, including the yersiniabactin system, are highly expressed by bacteria during 
natural uncomplicated UTI.  
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Materials and methods 
Ethical statement.  
All protocols involving human subjects were approved by the Institutional 
Review Board of the University of Michigan Medical School (HUM00029910). Written 
consent was obtained from all subjects prior to enrollment and patient samples were de-
identified. All mouse experimental procedures were conducted in accordance to protocols 
approved by the University Committee on Use and Care of Animals at the University of 
Michigan. 
 
E. coli gene expression during human infection.  
Urine samples collected from women with cystitis at the University Health 
Services Clinic were immediately stabilized with RNAprotect (Qiagen) to preserve 
bacterial RNA transcriptional profiles. Bacteria were pelleted by centrifugation, treated 
with Proteinase K (0.06 mAU/µl), and RNA was extracted with the RNeasy mini kit 
(Qiagen). DNA was removed by Turbo DNase (Ambion) treatment and RNA integrity 
assessed by Bioanalyzer (Agilent). Isolated E. coli strains were also cultured statically at 
37°C in pooled, filter-sterilized human urine and LB to mid-log phase and processed 
following the same protocol. Cystitis RNA samples were depleted of human RNA using 
the MICROBEnrich kit (Ambion). Sequencing libraries were generated using the Ovation 
Prokaryotic RNAseq system (NuGen) and the Encore next generation sequencing library 
system (NuGen).  
Libraries were sequenced using an Illumina HiSeq2000 at the Institute for 
Genome Sciences at the University of Maryland, Baltimore. Illumina reads were 
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analyzed using an automated pipeline (172) and Bowtie (173) was used to align the reads 
to the sequenced reference genome of the isolate (174). Gene expression was calculated 
as reads per kilobase of a gene per million mapped reads (RPKM) (175). Differences in 
gene expression exhibited by each E. coli strain in two samples (urine, UTI, or LB) were 
determined by calculating the log2 fold change (FC) of the RPKM values. A 
comprehensive report of this clinical study is presented by Subashchandrabose and 
colleagues (Subashchandrabose S. et al., submitted). A heat map of differential gene 
expression was produced in R version 2.15.1 (R Development Core Team) (176) with the 
package ‘pheatmap’ (177) and histograms of transcript abundance were generated with 
Artemis (Wellcome Trust Sanger Institute) (178).  
 
Bacterial strains and culture conditions.  
E. coli strains were cultured in lysogeny broth (LB; 10 g/liter tryptone, 5 g/liter 
yeast extract, 0.5 g/liter NaCl) at 37°C with aeration. E. coli strain 536 was isolated from 
the urine of a patient with UTI (168), and E. coli cystitis strains HM27, HM46, HM65, 
and HM69 were cultured from the urine of women presenting with cystitis at the 
University of Michigan University Health Services clinic, Ann Arbor, MI, USA.  
 
Mutant construction and cloning.   
An isogenic mutant unable to import yersiniabactin (536ΔfyuA::kan) was 
generated in E. coli 536 using the λ Red recombinase system (179) as described (115). 
Briefly, a kanamycin resistance cassette was PCR-amplified from the template plasmid 
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pKD4 using primers containing regions identical to the 5’ and 3’ ends of the gene fyuA 
from E. coli strain 536, shown underlined: 
fwd: GGCTTTATCCTCTGGCCTTGGGGGGATTATTGCTCCCCGCCGTGTAGGCTGGAGCTGCTTC 
rev: CGTATTGATACCGACGGTGCGACCCATATTGACCTGCGCGATGGGAATTAGCCATGGTCC. 
The resulting PCR product was used to replace the fyuA gene by homologous 
recombination in bacteria expressing Red recombinase from pKD46. The mutant was 
confirmed by PCR.  
 
Murine model of ascending UTI.   
Six-to-eight week old, female CBA/J mice (Harlan Laboratories) were inoculated 
transurethrally as described (149) using a modification of the Hagberg protocol (180). 
Bacteria were cultured overnight in LB at 37°C with aeration, harvested by centrifugation 
(3,000 × g for 30 min), and resuspended in phosphate-buffered saline (PBS) (128 mM 
NaCl, 2.7 mM KCl, pH 7.4) to an OD600 of 4.0 (4 × 109 CFU/ml). 50 µl of this 
suspension (containing 1 × 108 CFU) was delivered to each mouse via a sterile 0.28 mm 
polyethylene catheter attached to an infusion pump (Harvard Apparatus) with a flow rate 
of 100 µl/min. In competition (cochallenge) experiments, mice were inoculated with 50 
µl of a 1:1 mixture of the yersiniabactin receptor mutant (536ΔfyuA::kan) and wild type 
536 E. coli for a total of 1 × 108 CFU of total bacteria/mouse. Total CFUs for each 
inoculum was quantified by plating dilutions onto LB agar with or without kanamycin 
(25 µg/ml) to differentiate inoculating strains when appropriate. After 48 h, mice were 
euthanized and bladders, kidneys, and spleens were removed and homogenized in 3 ml 
PBS using an Omni GLH homogenizer (Omni International). Homogenized organs were 
plated onto LB agar plates with or without kanamycin (25 µg/ml), using an Autoplate 
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4000 spiral plater (Spiral Biotech) and total CFU/g tissue was determined (output) for 
each inoculating strain. For cochallenge experiments with two inoculated strains, 
competitive indices (C.I.) were calculated by dividing the ratio of the mutant to wild type 
in the output by the ratio of the mutant to wild type in the inoculum [(CFUΔfyuA/ 
CFU536)output/(CFUΔfyuA/ CFU536)inoculum]. Coinoculated strains that colonize to a similar 
level would have a C.I.=1. Mutant strains with reduced colonization fitness in 
comparison to wild type would have a C.I.<1 and strains with enhanced colonization 
fitness would have a C.I.>1. 
 
Murine model of bacteremia.   
Six-to-eight week old, female CBA/J mice (Harlan Laboratories) were inoculated 
via tail vein injection with 100 µl of a 1:1 mixture of E. coli strains 536 and 
536ΔfyuA::kan for a total  of 1 × 107 CFU/mouse. After 21 h, mice were euthanized and 
kidneys, spleen, and liver were removed. Organs were homogenized in 3 ml PBS and 
plated onto LB agar plates with or without kanamycin (25 µg/ml), to quantify CFU/g 
tissue. Colonization fitness was calculated by a competitive index (C.I.) as described 
above.  
 
Vaccine antigen preparation.   
The gene encoding the yersiniabactin receptor, fyuA, was PCR-amplified from E. 
coli 536 genomic DNA and cloned into the expression vector pBAD-myc-HisA 
(Invitrogen). Recombinant FyuA expression was induced in E. coli TOP10 cells cultured 
in Terrific broth (12 g/liter tryptone, 24 g/liter yeast extract, 4 ml/liter glycerol, 100 
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ml/liter filter-sterilized 0.17 M KH2PO4 and 0.72 M K2HPO4) at 37°C with aeration to an 
OD600=0.8 by the addition of 1 mM L-arabinose. After 4 h, the induced bacterial cultures 
were harvested by centrifugation (8,000 × g, 10 min, 4°C) and resuspended in 10 mM 
HEPES, pH 7, and 100 U benzonase nuclease (Sigma-Aldrich). Bacteria were lysed by 
two passages through a French pressure cell (20,000 psi) and the lysate cleared by 
centrifugation (8,000 × g, 10 min, 4°C). Bacterial membranes were pelleted from the 
cleared lysate by ultracentrifugation (112,000 × g, 30 min, 4°C) and solubilized in 5 ml 
of 100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, pH 8.0. Recombinant His6-tagged 
FyuA was purified on nickel-nitriloacetic acid-agarose columns (Qiagen) under 
denaturing conditions according to the manufacturer’s instructions (The 
QIAexpressionist). Eluted FyuA-His6 was renatured by four successive dialysis steps at 
4°C (buffer 1: 100 mM NaH2PO4, 5 mM Tris-HCl, 6 M urea, 50 mM NaCl, pH 5.5; 
buffer 2: 100 mM NaH2PO4, 2.5 mM Tris-HCl, 4 M urea, 100 mM NaCl, 0.005% 
Zwittergent, pH 6.5; buffer 3: 100 mM NaH2PO4, 2 M urea, 150 mM NaCl, 0.01% 
Zwittergent, pH 7.4) into a final solution of 0.05% Zwittergent in PBS, pH 7.4, and 
quantified by the bicinchoninic acid (BCA) protein assay (Pierce).  
 
Vaccination.   
Purified, renatured, recombinant FyuA was chemically cross-linked to cholera 
toxin (CT) (Sigma-Aldrich) at a ratio if 10:1 using N-succinimidyl 3-(2-
pyridyldithio)propionate (SPDP) (Pierce) according to the manufacturer’s 
recommendations. Cross-linked FyuA-CT was administered to six-to-eight week old 
female CBA/J mice (Harlan Laboratories) intranasally at 20 µl/mouse (10 µl/nare). A 
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primary dose of 100 µg FyuA cross-linked to 10 µg CT was administered on day 0 and 
two booster doses of 25 µg FyuA cross-linked to 2.5 µg CT were administered on days 7 
and 14. On day 21, mice were challenged transurethrally with E. coli as described in the 
murine model of ascending UTI.  
 
Monoclonal antibody generation.  
Three female BALB/c mice aged six-eight weeks were each immunized 
intraperitoneally with 10, 20, or 50 µg of purified, renatured, recombinant FyuA 
emulsified in complete Freund’s adjuvant (Sigma-Aldrich) on day 0, followed by booster 
injections of 10, 20 and 50 µg (respectively) of FyuA with incomplete Freund’s adjuvant 
(Sigma-Aldrich) on days 14, 42, and 56. The induction of FyuA-specific antibodies 
in serum was monitored by enzyme-linked immunosorbent assay (ELISA), and on day 
60, the animal with the highest level of FyuA-specific antibodies was euthanized and the 
spleen removed. Harvested spleenocytes were fused to the murine cell line P3X63-
Ag8.653 (181) using polyethylene glycol and conventional somatic cell hybridization 
techniques (182, 183) and the resulting hybridoma clones were screened for FyuA-
specific antibody production by ELISA, Western blot, and flow cytometry. The 
monoclonal antibody (mAb) selected for the highest affinity for FyuA (5E7.22) was 
isotyped as IgG2bκ using a Pierce Rapid ELISA mouse mAb isotyping kit 
(ThermoFisher). 
 
Flow cytometric analysis of yersiniabactin receptor surface accessibility.  
Iron receptor expression was induced in wild type E. coli 536 and mutant 
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536ΔfyuA::kan by diluting overnight cultures 1:50 into fresh LB with 200 µM 2,2’-
dipyridyl (DPD) (Sigma-Aldrich), and allowing cultures to incubate at 37°C with 
aeration for 6 h. Cultures were pelleted, washed with PBS, and incubated in undiluted 
supernatant from the FyuA-specific hybridoma clone 5E7.22 for 30 min at room 
temperature. FyuA-specific antibody binding was quantified by staining with the 
secondary antibody Fluorescein (FITC)-conjugated goat anti-mouse IgG (H+L) (Jackson 
ImmunoResearch) diluted 1:100 in PBS at room temperature for 30 min and analyzed by 
FACSCanto (Becton, Dickinson and Co.). E. coli cultured in iron-replete conditions, 
stably expressing GFP, or stained with only secondary antibody were used as controls for 
the assay. Histograms were produced with FlowJo software (Tree Star Inc.). 
 
Statistical analysis.   
Significance was assessed using a two-tailed Mann-Whitney test or a Wilcoxon 
signed rank test with a theoretical median of zero, when appropriate. All P values are 
two-tailed at a 95% confidence interval. Analyses were performed using GraphPad 
Prism, version 6.0d (GraphPad Software, San Diego, CA).     
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Results 
The yersiniabactin system is highly expressed during uncomplicated UTI.  
To determine if bacterial iron acquisition systems are expressed during natural, 
uncomplicated UTI, urine was collected and immediately stabilized with RNAprotect 
from women seeking treatment for cystitis at the University of Michigan University 
Health Services Clinic. Of the 86 urine samples collected, 42 were positive for bacteria 
by culture, and of those 38 (90%) contained E. coli at ≥105 CFU/ml. An additional four 
species were isolated: Citrobacter freundii, Citrobacter koseri, Enterobacter aerogenes, 
and Proteus mirabilis. Bacterial RNA transcript levels from five E. coli samples were 
quantified by RNAseq analysis and four mapped sufficiently to their respective genomes 
for quantification (174). To provide comparison, RNAseq analyses were also performed 
on RNA isolated from the same four E. coli strains cultured in LB (an iron-replete 
medium) and filter-sterilized human urine, which is naturally iron-limited. All four UTI 
isolates during natural bladder infection had measurable RNA transcript levels for 
bacterial genes involved in iron acquisition, mirroring levels observed during culture in 
human urine, as compared to LB (Figure 3-1). Of the three E. coli siderophore systems 
that are pathogen-associated (salmochelin, aerobactin, and yersiniabactin), the 
yersiniabactin system was the most prevalent, found in three of the four isolates (Figure 
3-1). Our observations support previous molecular epidemiological data on UPEC 
virulence factors, which found that 87% of cystitis E. coli isolate genomes encoded fyuA, 
compared to 74% and 35% for iroN (salmochelin) and iutA (aerobactin), respectively 
(184). Transcript levels for the gene fyuA were among the most abundant, as all three 
yersiniabactin-encoding isolates had fyuA in the top 15% of genes expressed during 
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cystitis, as compared to growth in LB (HM27:11.1%, HM69:10.4%, HM65:14.4%). 
Transcriptional start sites in the yersiniabactin operon could also be predicted by a 
histogram of transcript abundance, suggesting strong induction of the promoter upstream 
of ybtA, which encodes an AraC-like transcriptional activator of fyuA (185), and the 
promoter directly upstream of fyuA (Figure 3-2).  
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Figure 3-1. UPEC iron acquisition gene expression by E. coli strains during cystitis 
in women versus culture in urine. Fresh urine samples from four women with 
uncomplicated E. coli UTI were stabilized immediately and processed for bacterial RNA 
(HM46, HM69, HM65, HM27). RNA transcript levels were quantified by RNAseq and 
compared to transcript levels in the same strains during culture in human urine and LB. 
Differential transcript abundance between UTI or urine compared to LB for each gene is 
presented as the log2-fold change (FC) and visualized on a heat map. Genes with more 
abundant RNA transcripts during cystitis or cultured growth in urine in comparison to 
growth in LB are colored darker red. Genes not present in the genome of the isolate are 
left white.  
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Figure 3-2. RNAseq read coverage of the yersiniabactin operon in E. coli cultured in 
human urine. Histogram displaying sequence coverage per nucleotide for reads mapped 
to the yersiniabactin operon of the E. coli HM27 genome from RNAseq data of E. coli 
HM27 cultured in urine. Open reading frames are illustrated below the histogram with 
known promoter regions identified. The genes ybtA and fyuA, which encode an AraC-like 
transcriptional activator of fyuA and the yersiniabactin receptor FyuA, respectively, are 
highlighted. Genes irp2, irp1, ybtU, ybtT, ybtE and ybtS encode proteins involved in 
yersiniabactin synthesis, ybtP, ybtQ, and fyuA encode proteins that facilitate 
yersiniabactin transport, and ybtX is of unknown function (186).  
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Blocking yersiniabactin attenuates UPEC during UTI.  
The yersiniabactin receptor, FyuA, is an effective vaccine target to prevent 
pyelonephritis, but not cystitis (119). Given that gene expression studies from 
experimental infection in mice (109) and now natural uncomplicated infections in women 
indicate that iron acquisition systems are highly expressed by bacteria infecting the 
bladder, the lack of bladder protection by an FyuA-based vaccine is surprising. One 
possible mechanism for this organ-specific immunity is that the yersiniabactin system 
mediates infection of the kidneys, but not the bladder. To test whether the yersiniabactin 
system contributes to E. coli pathogenesis in the urinary tract, we evaluated the virulence 
of an E. coli mutant unable to acquire iron by yersiniabactin during infection. Mice 
inoculated transurethrally with wild type E. coli 536 had significantly higher bacterial 
colonization in the bladder and the kidneys compared to mice inoculated with an isogenic 
mutant deficient in the yersiniabactin receptor (ΔfyuA) (Figure 3-3). These data support 
yersiniabactin as a significant E. coli virulence factor in the bladder and kidneys and 
suggest that the failure of an FyuA-based vaccine to prevent cystitis may be due to 
immunological differences, such as antibody concentration, between the bladder and the 
kidneys, rather than differences in E. coli pathogenesis.  
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Figure 3-3. Blocking yersiniabactin import attenuates E. coli during UTI. Female 
CBA/J mice were transurethrally inoculated with 1×108 CFU of E. coli 536 or E. coli 
536ΔfyuA in independent challenge and colonization was measured 48 hours post 
inoculation. Data from two independent experiments are presented with the total number 
of animals per group being N=20 (536) and N=20 (536ΔfyuA). Symbols represent CFU/g 
tissue from an individual mouse and bars indicate median values. Dashed line shows the 
limit of detection for the assay, 100 CFU/g. Significance was determined using a two-
tailed Mann-Whitney test.   
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Recombinant FyuA vaccine is target-specific.  
The yersiniabactin iron acquisition system facilitates E. coli infection of the 
kidneys and bladder, but immunization with a recombinant FyuA-based vaccine only 
protects against pyelonephritis, not cystitis (119). To confirm that the protective target of 
the FyuA vaccine is indeed the yersiniabactin receptor, mice were immunized and then 
cochallenged with a mixture of two isogenic E. coli strains: wild type 536 that produces 
FyuA, and 536ΔfyuA::kan that does not. E. coli expressing FyuA have a substantial 
fitness advantage in the urinary tract (Figure 3-3), but in the presence of an FyuA-specific 
immune response, we hypothesized that the advantage would be reduced or lost. Female 
CBA/J mice were intranasally immunized on day 0 with a primary dose of FyuA 
crosslinked to cholera toxin (CT) as adjuvant or CT alone, and then boosted with a 
quarter dose on days 7 and 14. On day 21, mice were transurethrally coinoculated with a 
1:1 mixture of 536 and 536ΔfyuA::kan. After 48 hours post infection, mice were 
euthanized and organs were removed to quantify the level of bacterial infection from 
each strain. As expected, wild type E. coli outcompeted the ΔfyuA mutant when infecting 
the bladder and kidneys of control mice immunized with only adjuvant (Figure 3-4A) 
reinforcing the observation that FyuA acts as an UPEC virulence factor during UTI 
(Figure 3-3). Furthermore, in the five mice that had their infection reach the spleen, wild 
type E. coli was found exclusively, further supporting the role of the yersiniabactin 
system during systemic infection (Figure 3-4A). However, when mice were immunized 
with FyuA-CT prior to experimental infection, wild type E. coli lost its fitness advantage 
over the ΔfyuA mutant, exclusively in the kidneys (Figure 3-4B). The kidney-specific 
attenuation of wild type E. coli is consistent with the kidney-specific protection of the 
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FyuA vaccine previously observed (119) and confirms the yersiniabactin receptor, FyuA, 
as the protective target of the FyuA vaccine.   
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Figure 3-4. FyuA vaccine is specific for the yersiniabactin receptor. Female CBA/J 
mice immunized with CT (A), or FyuA-CT (B) were transurethrally co-inoculated with a 
mixture of E. coli strains 536 and 536ΔfyuA::kan. Colonization was measured 48 hours post 
infection by plating for CFU/g tissue and competitive indices (C.I.) were calculated by 
dividing the fraction of the ΔfyuA mutant in the output (CFU/g tissue) by the fraction of the 
ΔfyuA mutant in the input (CFU/ml inoculum). Solid lines represent the median value for 
each group and the dashed line indicates a theoretical median of zero. Symbols represent the 
C.I. of an organ from a single mouse. Data were validated by two independent experiments 
for a total of 16 mice per group, with the exception of the spleen that only had 10 mice per 
group. Significance was determined by the Wilcoxon signed rank test with a theoretical 
median of zero. P-values for each group from left to right: (A) 0.2293, 0.0005, 0.0625, (B) 
0.0245, 0.2402, NA (all spleens from the FyuA-CT-immunized mice were uninfected). 
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Yersiniabactin contributes to UPEC pathogenesis during systemic infection.  
During severe infection, bacteria infecting the kidneys can breach epithelial and 
endothelial barriers to gain access to the bloodstream, causing systemic and life-
threatening disease (161). Since blocking yersiniabactin attenuates E. coli in the urinary 
tract, and FyuA-immunized mice are protected from systemic infection (113), we 
hypothesized that the yersiniabactin system may contribute to E. coli pathogenesis during 
bacteremia. To test this, mice were challenged systemically by intravenous injection with 
a 1:1 mixture of wild type E. coli 536 and an isogenic mutant unable to import 
yersiniabactin. After 21 hours post infection, the E. coli mutant unable to acquire iron by 
the yersiniabactin system was significantly outcompeted by wild type E. coli in the spleen 
and kidneys (Figure 3-5), indicating that iron acquisition by the yersiniabactin system 
contributes significantly to UPEC pathogenesis during bacteremia.  
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Figure 3-5. Blocking yersiniabactin import attenuates E. coli during systemic 
infection. Ten female CBA/J mice were intravenously co-inoculated with an equal 
mixture of wild type E. coli 536 and E. coli 536ΔfyuA::kan and organ colonization was 
measured 21 hours post inoculation. Competitive indices were calculated by dividing the 
fraction of the mutant in the output (CFU/g tissue) by the fraction of the mutant in the 
input (CFU/g inoculum). The median value for each group is represented as a solid line 
and the dashed line indicates a theoretical median of zero, which would occur if both wild 
type and mutant E. coli had equal representation in both the input and output. Three mice 
succumbed to the infection before being euthanized and are were excluded from the 
analysis. Significance was determined by the Wilcoxon signed rank test with a theoretical 
median of zero, and the P-value for each group was 0.0313 for the kidneys and 0.0313 
for the spleen.  
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The yersiniabactin receptor is accessible on the bacterial cell surface.  
Preventing iron acquisition by yersiniabactin attenuates UPEC in the urinary tract 
and bloodstream. Therapeutically blocking the yersiniabactin system, either with vaccine-
induced antibodies or a pharmaceutical agent, would likely be simplest by targeting the 
siderophore receptor, FyuA, on the bacterial outer membrane. To confirm that FyuA is 
exposed and accessible on the cell surface, despite the presence of capsule and surface 
polysaccharides, we developed an FyuA-specific monoclonal antibody (mAb) and 
quantified cell surface binding by flow cytometry. E. coli 536 cultured under iron-
limitation, mimicking conditions during infection, had a dramatic increase in median 
fluorescence intensity in comparison to an FyuA-deficient isogenic mutant (536ΔfyuA), 
indicating that a portion of FyuA is accessible to antibody binding on the bacterial cell 
surface (Figure 3-6).  
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Figure 3-6. Yersiniabactin receptor is surface-exposed and accessible to antibodies. 
Histogram overlay of FyuA surface expression and antibody binding as assessed by flow 
cytometry. UPEC strains 536 and 536ΔfyuA were cultured under iron-limitation and 
incubated with an FyuA-specific mAb (5E7.22), followed by a secondary antibody 
conjugated to FITC. Shaded area represents a control E. coli strain unable to express 
FyuA (536ΔfyuA), and the unshaded area denotes antibody binding to wild type E. coli.  
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FyuA is highly conserved among pathogens in the family Enterobacteriaceae. 
 To determine the degree of conservation of the yersiniabactin receptor, FyuA, at 
the amino acid sequence level between E. coli and K. pneumoniae strains, sequences of 
FyuA from 20 E. coli strains and 17 K. pneumoniae strains chosen at random were 
aligned and compared using the Clustal Omega sequence alignment tool (187). A high 
level of conservation was observed, as pairwise alignments were greater than 99.3% 
identical for all 37 aligned sequences (Figure 3-7). In addition, a high level of sequence 
conservation between strains was observed on the surface-exposed face of FyuA, as 
predicted by the tool PRED-TMBB based on a Hidden Markov Model (188), and shown 
on the crystalized structure of FyuA (Figure 3-7A, B) (189). 
 To evaluate the level of FyuA amino acid sequence conservation between 
multiple pathogenic members of the family Enterobacteriaceae, consensus sequences 
were generated and compared between the species E. coli, K. pneumoniae, K. oxytoca, Y. 
pestis, Y. enterocolitica, Y. pseudotuberculosis, S. enterica, and Citrobacter koseri 
(Figure 3-8). Although increased variability exisits in the amino acid alignments for 
FyuA between the multiple species evaluated, a high degree of conservation can still be 
observed, as all pairwise alignments were greater than 92.0% identical (Figure 3-8).  
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Figure 3-7. FyuA amino acid sequence is highly conserved between Escherichia coli 
and Klebsiella pneumoniae strains. Cartoon (A) and surface view of the extracellular 
face (B) of the crystal structure of FyuA (PDB: 4EPA) (189) colored for conservation 
between a total of 20 E. coli and 17 K. pneumoniae strains sampled at random. Grey is 
100%, violet >90%, and orange 85-90% conservation. (C) Sequence map of FyuA with 
extracellular exposed sequences as predicted by a Hidden Markov Model (PRED-TMBB) 
underlined in green (188). Individual amino acids are coded by the same conservation 
color scheme. Turquoise bar corresponds to FyuA plug domain, provided for reference. 
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Figure 3-8. FyuA amino acid sequence is highly conserved among pathogenic species 
in the family Enterobacteriaceae. FyuA consensus sequences generated with Clustal 
Omega from pathogenic species in the family Enterobacteriaceae are compared. Dark 
and light blue indicate complete or >80% identity respectively. A consenus sequence for 
all evaluated sequences is provided and the plug domain is highlighted in turquoise and 
extracellular exposed residues as predicted by PRED-TMBB are highlighted in green. 
Number of sequences used to generate consenus sequences: 20 E. coli, 17 K. 
pneumoniae, 13 K. oxytoca, 17 Y. pestis, 8 Y. enterocolitica, 3 Y. pseudotuberculosis, 2 
S. enterica, 1 Citrobacter koseri. 
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Discussion 
Here we demonstrate the yersiniabactin receptor to be a virulence factor for 
UPEC during cystitis and pyelonephritis, a fitness factor during bacteremia, and the 
specific, surface-accessible target of the experimental FyuA vaccine. Furthermore, we 
show that genes encoding bacterial systems for iron acquisition, including the 
yersiniabactin system, are highly expressed during natural, uncomplicated cystitis in 
women. Overall, our data support the yersiniabactin system as a therapeutic target to 
prevent or treat UPEC-mediated UTI, and reinforce the potential of the yersiniabactin 
system as a common target for several, increasingly multidrug-resistant, Gram-negative 
enteric pathogens (189, 190). 
Given that UPEC strains frequently encode numerous, often-redundant iron 
acquisition systems, the ability to attenuate infection by targeting just a single system is 
surprising. While individual iron uptake mechanisms uniquely contribute to bacterial 
pathogenesis (115, 191), it seems reasonable to assume their similar function would allow 
for compensation. Of the four siderophores UPEC isolates produce, three are so-called 
‘stealth’ siderophores (salmochelin, yersiniabactin, aerobactin) for their ability to avoid 
sequestration by lipocalin-2 (191, 192). Isolating UPEC strains with all three stealth 
siderophore systems is uncommon, possibly due to their outer membrane receptors being 
the frequent target of bacteriophages and bacteriocins (193). UPEC strain 536 synthesizes 
two of these stealth siderophores: salmochelin and yersiniabactin, but not aerobactin. It is 
possible that the less common aerobactin system may compensate for the loss of 
yersiniabactin during E. coli UTI, but this remains to be tested.  
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Although the protective mechanism of the kidney-specific FyuA vaccine is 
unknown, high fyuA expression and significant FyuA-mediated virulence during cystitis 
suggest that the absence of vaccine protection in the bladder (119) is not due to reduced 
yersiniabactin expression or pathogenesis in this organ. Thus immunological differences 
between the bladder and kidneys may explain the disparity in vaccine efficacy between 
tissues. Indeed, despite being prone to recurrent infection, the immunological networks of 
the bladder are distinct from the kidney and remain poorly defined (194). Therefore it 
may be possible to extend the protection of the FyuA vaccine to the bladder by modifying 
the immunization route, formula, adjuvant, or timeline to improve the adaptive immune 
response in the bladder. 
Lastly, since yersiniabactin is predominantly associated with highly pathogenic 
strains and a major virulence factor for several pathogenic bacteria in the family 
Enterobacteriaceae, targeting FyuA may provide a mechanism to specifically eliminate 
disease-causing bacteria without harming the beneficial bacteria comprising the 
microbiome, which is a common side effect of conventional antibiotics (195). In addition, 
yersiniabactin is disproportionately associated with antibiotic-resistant strains, including 
>90% of the E. coli sequence type 131 (ST131) an alarming pandemic multidrug-
resistant (MDR) clonal group (196-199), and >60% of respiratory carbapenemase-
producing K. pneumoniae strains, as compared to 10% of susceptible K. pneumoniae 
strains (192). Novel antimicrobial agents or vaccines that target yersiniabactin iron 
transport, or other pathogen-associated nutrient acquisition systems may provide an 
effective strategy to combat the rising surge of antibiotic-resistant common infections. 
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CHAPTER 4 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
Summary of Results 
Here we presented studies that addressed the potential of select UPEC outer 
membrane iron receptors to be used as vaccine candidates to protect against UTI, and 
tested the contribution of the yersiniabactin receptor, FyuA, to UPEC pathogenesis 
during UTI and systemic infection. The major findings of this dissertation are briefly 
described: 
• Intranasal immunization with the vaccine candidate FyuA protected CBA/J mice 
from experimental UTI, but IroN, FitA, ChuA fragments, and the gene product of 
CFT073 locus c0294, did not. 
• Immunization with FyuA protected mice from experimental pyelonephritis, but 
not cystitis, and elicited a sustained and robust FyuA-specific serum IgG response 
that correlated with levels of UPEC colonization in the kidney, but not in the 
bladder.  
• Bacterial RNA transcript levels for genes encoding proteins involved in iron 
acquisition were highly abundant in UPEC strains causing natural uncomplicated 
cystitis in women.   
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• The yersiniabactin receptor, FyuA, contributes to UPEC virulence during 
experimental cystitis and pyelonephritis, and to UPEC fitness during bacteremia.  
• The experimental FyuA vaccine is specific for its target, FyuA, which is exposed 
and accessible to antibody binding on the E. coli outer membrane.  
• FyuA is highly conserved at the amino acid level among E. coli and K. 
pneumoniae strains and provides a common narrow-spectrum therapeutic target 
for current outbreaks of carbapenem-resistant Enterobacteriaceae.  
 
Conclusions and Perspectives 
The data presented here strongly support a role for FyuA and yersiniabactin-
mediated iron acquisition by UPEC during UTI. Of the six outer membrane iron receptor 
vaccine candidates tested in a mouse model of ascending UTI, the yersiniabactin 
receptor, FyuA, was the only protective candidate identified from the screen. In addition, 
a UPEC mutant unable to acquire yersiniabactin during infection was significantly 
outcompeted by wild type in the bladder, kidneys, and spleen. While we present strong 
evidence supporting the contribution of the yersiniabactin system to UPEC pathogenesis 
and its potential as a therapeutic target, a number of questions remain.  
 The specific mechanism(s) of protection for the experimental FyuA vaccine 
remain to be clearly defined. We hypothesize that vaccine protection is humorally-
mediated, as there is ample evidence to suggest a role for antibodies during UPEC 
clearance. Naïve mice passively immunized with anti-ovalbumin (OVA) antibodies were 
protected from experimental UTI by a UPEC strain engineered to express the highly-
antigenic OVA antigen (33), and naïve mice passively immunized with rabbit antisera 
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raised against UPEC iron receptors, including FyuA, were protected from lethal 
challenge by UPEC in a model of systemic infection (200). However, establishing that 
antibodies raised against natural UPEC antigens can passively protect against UPEC 
infection in the urinary tract has proven to be more difficult. An attempt to passively 
immunize naïve mice with mouse polyclonal FyuA antisera was unsuccessful (Figure A-
1), as was an attempt to produce a therapeutic FyuA-specific monoclonal antibody 
(Appendix B).  
We hypothesize that there are two reasons why passive protection in the urinary 
tract has been more difficult to achieve than in a model of systemic infection. First, the 
delivery of sufficient quantities of antibodies to the urinary tract may be a substantial 
hurdle. Antibodies delivered to mice by intraperitoneal injection quickly transferred from 
the peritoneal cavity to the bloodstream, within hours of injection (201), as validated by 
ELISA (Figure B-6). However, intraperitoneally-injected antibodies were not 
significantly detected in the urine of passively immunized mice 16 hours after injection 
(Figure B-6), suggesting that antibodies delivered to the peritoneal cavity are not 
efficiently transferred to the urinary tract. Poor or slow antibody delivery to the urinary 
tract may provide an explanation for why attempts to passively immunize mice against 
UTI were unsuccessful, including attempts with highly concentrated antisera raised 
against O-polysaccharide (O6), a UPEC antigen prevalent on the bacterial cell surface 
(data not shown).  
Secondly, polyclonal FyuA antisera raised from intranasally-immunized mice 
may not provide sufficient antibody levels to passively protect naïve mice. Intranasal 
immunization with hydrophobic, insoluble iron receptors, such as FyuA, induced variable 
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levels of serum antibody (Figure 2-6), likely due to inconsistent dosing between animals. 
Pooled sera from multiple immunized mice may dilute the protective vaccine-specific 
antibodies generated, and low antibody levels coupled with poor or slow antibody 
delivery into the urinary tract from intraperitoneal injection may impede successful 
passive protection. Thus, the lack of UTI protection observed after passive immunization 
is likely the result of technical hurdles preventing the delivery of highly concentrated 
antisera into the urinary tract.  
Understanding the specific role of vaccine-generated antibodies during infection 
can facilitate vaccine development by guiding the optimization of immunization route, 
dose, adjuvant, and timeline to better induce the specific protective component(s) of the 
vaccine-generated immune response. For example, although, we found FyuA-specific 
serum IgG levels to correlate with protection in the kidney, it is unclear if serum IgG 
plays a direct role in UPEC clearance from the urinary tract, or if it is only a marker for 
antibody class switching in B cells and the induction of an FyuA-specific adaptive 
immune response. If serum IgG plays a direct role in UPEC clearance, alternative routes 
of immunization such as intramuscular injection and adjuvants can be used to induce a 
more robust serum IgG response, and possibly improve vaccine protection. Identifying 
the specific immune system mechanisms that contribute to protection would be extremely 
beneficial, and immunization experiments using mouse knockout models deficient in 
specific components of the adaptive immune system may provide a more specific way to 
evaluate the role of the adaptive immune system in vaccine protection of the urinary tract.  
 Although we hypothesize that vaccine-induced bacterial clearance is mediated 
primarily by antibody opsonization, another possible mechanism may be the generation 
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of antibodies that bind to iron receptors and inhibit their function. Blocking 
yersiniabactin acquisition by FyuA attenuated UPEC during UTI, as did blocking heme 
uptake by the heme receptor Hma (202), and blocking aerobactin uptake by IutA (107). 
All three of these outer membrane receptors are protective vaccine targets for UPEC UTI 
(32, 119). The organ-specific protection induced by immunization closely correlates with 
the organ-specific attenuation observed by blocking receptor function. Immunizing mice 
with Hma protected against pyelonephritis, but not cystitis (32), and blocking Hma heme 
acquisition attenuated UPEC in the kidney, but not the bladder (202). Immunizing mice 
with IutA protected against both pyelonephritis and cystitis (32), and blocking aerobactin 
uptake by IutA attenuated UPEC in both the kidney and the bladder (107). Immunizing 
mice with FyuA protected against pyelonephritis and reduced cystitis, although not 
significantly (119), and blocking yersiniabactin acquisition attenuated UPEC in the 
kidney and bladder. Only the protective vaccine candidate, IreA, contravenes this trend. 
IreA is an iron regulated outer membrane receptor of unknown function (203), and mice 
immunized with IreA were protected against cystitis, but not pyelonephritis (32). 
However, IreA does not appear to contribute to the fitness of UPEC in the bladder or 
kidneys, as determined by coinfections with wild type UPEC and a ΔireA mutant (Figure 
D-1). Although IreA-neutralization by vaccine-induced antibodies does not appear to be a 
possible protective mechanism against cystitis in IreA-immunized mice, it does not 
invalidate the possibility that blocking receptor function by antibody binding may 
contribute to vaccine-induced protection by the other vaccine candidates FyuA, Hma, 
and, IutA. Indeed, antisera raised against Hma was able to significantly reduce the level 
of heme binding to recombinant Hma in vitro, as compared to pre-immune sera (204). 
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The full evaluation of whether vaccine-induced antibodies contribute to UPEC UTI 
protection through blocking iron receptor function requires further testing by cross-
feeding assays in the presence of vaccine-specific antibodies.  
  In addition to unanswered questions regarding the specific mechanism(s) of iron 
receptor vaccine protection, gene expression data from E. coli causing uncomplicated 
cystitis in women provoked new questions regarding UPEC pathogenesis during natural 
UTI. The quantification of RNA transcript levels with RNAseq from pathogenic E. coli 
directly stabilized from the urine of women with active infection supported a role for 
bacterial iron acquisition during human uncomplicated cystitis (Figure 3-1, 2), 
confirming studies in mice (205) and in patients with complicated UTI (206). In addition, 
the study revealed new UPEC UTI virulence determinants, such as a copper efflux 
system (Subashchandrabose et al., submitted), and confirmed previous UTI 
epidemiological studies that E. coli is the most prominent cystitis bacterial species (90%) 
and that antibiotic resistance to first-line therapeutics is prevalent (15.3% resistant to 
TMP-SMX, 7.7% resistant to Ciprofloxacin), though at lower levels than documented at 
the University of Michigan Hospital (27% resistant to TMP-SMX, 27% resistant to 
Ciprofloxacin) (Appendix E). However, RNAseq analysis of RNA transcripts allowed for 
very detailed and quantitative data on bacterial gene expression during infection, 
revealing substantial expression variability between isolates. RNA transcript levels for 
the gene fimA, which encodes the major structural subunit of type 1 fimbria, a virulence 
factor essential for UPEC colonization of the murine bladder (89), were among the top 
10% most abundant in two of the isolates (HM27 and HM46), but among the bottom 50% 
in abundance in isolates HM69 and HM65. The variability of type 1 fimbria expression 
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was confirmed by evaluating the orientation of the fim promoter, located on an invertible 
element upstream of fimA, in 21 of the stabilized UPEC cystitis samples (Figure E-1). 
Similar expression variability between isolates was noted for multiple fimbrial systems 
(Luterbach et al., unpublished) and metabolic systems (Alteri et al., unpublished) leading 
to questions about host differences, such as patient hydration level or immunity, and 
strain differences, such as phylogenetic group. Alternatively, variations in UPEC gene 
expression may represent various stages of UTI progression, a possibility that needs to be 
explored through single infection time courses.   
 The conditions of the urinary tract upon initial bacterial inoculation are likely very 
different from conditions after logarithmic bacterial growth and colonization, and even 
more dissimilar after the initiation and recruitment of a damaging inflammatory immune 
response. Dissolved urinary oxygen levels drop significantly during UTI (207), likely due 
to exhaustive bacterial aerobic respiration and rapid growth. Environmental oxygen 
levels influence vast networks of E. coli gene expression, causing shifts in metabolism 
(208), fimbrial expression (209), and virulence (210). After the recruitment of innate 
immune cells and the initiation of an inflammatory immune response, host and bacterial 
cell damage and debris can change the metabolites available to invading bacteria. 
Oxidative bursts from host innate immune cells can cause oxidative stress, leading to 
substantial shifts in UPEC gene expression, such as the down-regulation of genes 
involved in aerobic respiration and an increase in the expression of mechanisms to 
protect against harmful oxidative radicals (211). Thus, variations in UPEC gene 
expression between cystitis isolates may reflect various stages of UTI progression. 
Temporal gene expression changes during the course of infection have been documented 
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for other bacterial human pathogens, including Vibrio cholerae (212) and Mycobacterium 
tuberculosis (213). Resolving the dynamics of UPEC gene expression through the course 
of a natural UTI could influence our choice of an ideal vaccine target (expressed upon 
initial infection) and an ideal therapeutic target (expressed during mature or late 
infection) and further our understanding of UPEC pathogenesis and the host immune 
response.  
Finally, enrolling women in a clinical study with various histories of 
uncomplicated UTI presented an opportunity to evaluate the host adaptive immune 
response to UPEC at the time of infection. Serum collected from study participants was 
evaluated for UPEC-reactive antibodies by western blot and ELISA. Levels of serum 
reactivity to UPEC whole cell lysates by western blot did not correlate with patient UTI 
history (data not shown). Likewise, neither did serum reactivity to individual UPEC iron 
receptors (Figure E-2 and data not shown). These data support recent findings by Chan 
and colleagues identifying the bladder as an immune-privileged site (194), suggesting 
that poor adaptive immunity is generated after cystitis, leaving patients susceptible to 
recurrent infection. Interestingly, the serum from all patients assayed had detectable 
levels of FyuA-specific IgG antibodies, which raises the question of when the adaptive 
immune system has had contact with FyuA in patients with no history of UTI. The 
expression of iron receptors in other host sites, such as the gastrointestinal tract during 
periods of gut inflammation (214), may provide a possible explanation, but remains to be 
explored.  
 
  108 
Future Directions 
While the studies presented here provide a crucial first step in defining a role for 
yersiniabactin-mediated iron acquisition by UPEC during UTI and demonstrate FyuA as 
a promising vaccine target against UPEC, further work is needed to refine our 
understanding of the yersiniabactin system and iron acquisition as a therapeutic target for 
UTI, and a contributor to UPEC pathogenesis.  
Screening for UPEC iron receptors that protect against infection in a mouse model 
of UTI is just the initial step towards vaccine development and additional progress needs 
to be made to optimize the route, dose, adjuvant, delivery system, antigen composition, 
and immunization timeline. In addition, since much of our understanding of UPEC 
pathogenesis and vaccine protection is dependent on mouse models of infection, it 
behooves us to fully investigate the similarities and differences between natural human 
infection and experimental infection in mice. For example, preliminary evidence suggests 
that UPEC fimbrial expression is more diverse during human infection, than during 
experimental mouse infection (206), information that could have informed early clinical 
trials with adhesin-based vaccines (132). Thus, acknowledging and understanding the 
strengths and weaknesses of our model, which guides therapeutic design, would be a 
prudent investment, potentially saving us substantial time and resources before advancing 
ultimately to clinical trials.  
Finally, therapeutically targeting pathogen-associated bacterial iron receptors, 
such as yersiniabactin, provides a unique mechanism to eliminate predominantly disease-
causing bacterial strains while sparing the beneficial commensal bacteria of the 
gastrointestinal tract. However, we have a limited understanding of the role of E. coli iron 
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acquisition outside of the context of infection. Given that the urinary tract is an 
evolutionary ‘dead end’ for pathogenic E. coli, frequent iron receptor redundancy and 
diversity among pathogenic E. coli strains suggests that E. coli must encounter selective 
pressure for iron receptor diversity in an alternative host niche.  
The mammalian gastrointestinal tract, where E. coli resides as a member of the 
microbiota in healthy individuals, is a constantly changing environment with substantial 
microbial competition for resources, making it a logical candidate location for where the 
evolutionary expansion of resource acquisition systems could occur. Indeed, enteric 
bacteria that routinely compete for nutrients with a diverse and shifting array of microbial 
competitors commonly have substantial nutrient acquisition system redundancy. For 
example, the common gut bacterial species Bacteroides thetaiotaomicron has over 80 
systems dedicated to acquiring and processing dietary starch (215). Although the 
gastrointestinal tract is commonly thought of as a strictly anaerobic environment that is 
rich in dietary iron, during conditions of inflammation, facultative anaerobic species like 
E. coli bloom and microbial competition for iron intensifies (216). Indeed, the ‘probiotic’ 
E. coli strain Nissle 1917 was able to reduce the intestinal colonization of the enteric 
pathogen Salmonella enterica serovar Typhimurium in a mouse model of acute colitis by 
competing for iron resources with similar iron acquisition systems (214). E. coli iron 
acquisition system diversity and redundancy may be favored during periods of 
gastrointestinal inflammation, which then may give rise to strains that are able to colonize 
extraintestinal host niches.  
Although, large-scale gene expression studies in the gut are still difficult to 
accomplish due to the density of the microbiota, fluorescent markers driven by individual 
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gene promoters may provide a way to assess the expression of individual E. coli iron 
receptor genes in response to gut inflammation and provide a method to evaluate the 
requirement for iron acquisition in the gut. Clearly, effort needs to be made to understand 
the mechanisms that drive iron receptor acquisition and diversification among E. coli 
strains, which may inform why particular strains accumulate multiple iron acquisition 
systems, facilitating extraintestinal infection.  
Overall substantial work remains to fully understand UPEC pathogenesis in the 
urinary tract and persistence in the gastrointestinal tract, but the progress in UPEC 
vaccine development appears promising. New emerging technologies such as next 
generation sequencing allow UPEC gene expression to be evaluated during active human 
infection, facilitating new insights into bacterial pathogenesis and the host immune 
response to infection. These tools will help guide the development of novel vaccine 
strategies and therapeutics to combat the increasing prevalence of antibiotic resistant 
strains and further our understanding of UPEC pathogenesis during UTI.  
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Appendix A. Passive immunization with FyuA anti-sera 
 To determine if the protective mechanism of the experimental FyuA vaccine 
(119) was based on an FyuA-specific humoral immune response, naïve CBA/J mice were 
passively immunized with either pooled control sera, or FyuA-antisera before being 
challenged with a transurethral inoculation of UPEC. Mice given FyuA-antisera (FyuA) 
before UPEC challenge had no significant protection from UPEC infection in either the 
kidneys or the bladder, as compared to control mice (CT) (Figure A-1). We hypothesized 
that the lack of protection could be due to insufficient antibody transfer, given that 
passively immunized mice would have substantially less circulating anti-FyuA 
antibodies, as compared to mice actively immunized with the experimental FyuA 
vaccine.  
 
Figure A-1. Passive immunization of CBA/J mice using polyclonal FyuA-antisera. 
Six-to-eight week old female CBA/J mice were injected intraperitoneally with 200 µl of 
pooled serum from terminally bled female CBA/J mice, immunized with either purified 
recombinant FyuA-His6 conjugated to cholera toxin (CT) or CT alone. After 16 h, 
passively immunized mice were inoculated intraurethrally with 1 × 108 CFU UPEC. Mice 
were euthanized 48 hpi and organs were homogenized and CFU/g tissue was enumerated 
by plating onto LB agar.  
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Appendix B. Developing a therapeutic FyuA-specific monoclonal antibody 
Generating FyuA-specific spleenocytes 
To determine if passively immunizing mice with sufficient FyuA-specific 
antibodies could protect against UPEC UTI, we attempted to develop a therapeutic FyuA-
specific monoclonal antibody in conjunction with the University of Michigan Hybridoma 
Core facility. The FyuA-specific serum IgG response of FyuA-His6-immunized mice was 
monitored by ELISA (Figure B-1). Mouse two was euthanized and its spleen removed to 
harvest spleenocytes.  
 
Figure B-1. Monitoring levels of FyuA-specific serum IgG of FyuA-immunized mice 
in preparation to generate an FyuA-specific monoclonal antibody. Three 
female BALB/c mice aged six-to-eight weeks were each immunized 
intraperitoneally with 10, 20, or 50 µg of purified, renatured, recombinant FyuA-His6 
emulsified in complete Freund’s adjuvant (Sigma-Aldrich) on day 0, followed by booster 
injections of 10, 20 and 50 µg (respectively) of FyuA-His6 with incomplete Freund’s 
adjuvant (Sigma-Aldrich) on days 14, 42, and 56. The induction of FyuA-specific 
antibodies in serum was monitored by enzyme-linked immunosorbent assay (ELISA), 
and on day 60, the animal with the highest level of FyuA-specific antibodies (mouse 2) 
was euthanized and the spleen removed. 
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Screening hybridoma clones for FyuA-specificity by ELISA 
 Fused spleenocytes yielded 466 initial hybridoma clones that were screened by 
ELISA for FyuA-specific antibody production. Of these, 151 clones produced antibody 
that was specific to FyuA-His6, and of these, 80 clones maintained growth after two 
weeks. Following this initial screen, the remaining 80 viable clones were re-screened a 
second time for FyuA-specificity by ELISA, and 62 remained positive for FyuA-specific 
antibody production (Figure B-2). Of these, 36 clones maintained growth four weeks 
following fusion.  
 
 
 
Figure B-2. Screening hybridoma clones for FyuA-specific IgG production by 
ELISA. Histogram of 62 clones positive for the production of FyuA-specific IgG as 
determined by ELISA. Wells incubated with unused cell culture media (Media) and spent 
media from the spleenocyte fusion partner, melanoma cell line P3X63-Ag8.653 (Neg 
Sup), were used as a negative controls for FyuA binding activity. Positive clones were 
defined as having an absorbance 450 nm signal greater or equal to three times the 
negative control (Neg Sup) signal. 
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Screening hybridoma clones for FyuA-specific binding by western blot  
 Purified recombinant FyuA-His6 protein, used as vaccine and ELISA antigen, is 
enriched for FyuA-His6 through nickle-affinity chromotography, and still contains a small 
amount of contaminating proteins. To be sure that the hybridoma clones selected by 
ELISA for FyuA-His6-specific antibody production were specific for FyuA-His6, and not 
a minority protein contaminating the antigen preparation, positive hybridoma clones were 
screened for FyuA-specific binding by western blot. Of the 21 clones screened, 13 clones 
produced antibody that bound to a 75 kDa band, the size of FyuA-His6 (Figure B-3A), 
and 8 clones produced antibody that bound to a non-75 kDa band (Figure B-3B), or had 
no reactivity. Purified recombinant FyuA-His6 was separated by SDS-PAGE and stained 
for total protein to demonstrate level of purity (Figure B-3C). 
 
Figure B-3. Reactivity of hybridoma clone supernatant to FyuA-His6 and purity of 
FyuA-His6 protein preparation. Western blots demonstrating hybridoma supernantant 
reactivity to purified recombinant FyuA-His6, using a goat-α-mouse IgG-HRP as the 
secondary antibody (A, B). FyuA-specific clone 5E7 (A) and non-specific clone 8E10 (B) 
are used as representatives. A dilution curve of purified recombinant FyuA-His6 was 
separated by 10% SDS-PAGE and stained with the coomassie-based SimplyBlue 
SafeStain (Life Technologies) (C). Arrow indicates the location of FyuA-His6 (doublet) 
and the molecular weight of the protein standard bands, in kDa, are shown on the left.   
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Screening hybridoma clones for cell surface binding by flow cytometry 
 We hypothesized that a therapeutic FyuA-specific monoclonal antibody would 
need to bind to the surface-exposed region of FyuA on the bacterial cell surface to be 
effective at preventing UPEC infection. To screen hybridoma clones for the production of 
antibodies with specificity for surface-exposed domains of FyuA, the supernatant from 
clones positive for FyuA-specific antibody production, as determined by ELISA and 
western blot, were incubated with live E. coli bacterial cells, which were then stained 
with a FITC-conjugated secondary antibody and screened by flow cytometry. Wild type 
E. coli 536 expressing FyuA had a substantial increase in median fluorescence intensity 
as compared to an FyuA-deficient isogenic mutant (536ΔfyuA), when incubated with the 
clone 5E7.22 supernatant, indicating that a portion of FyuA is accessible to 5E7.22 mAb 
binding on the bacterial cell surface (Figure B-4A). Of the 27 hybridoma subcolones 
screened, 5E7.22 produced antibodies with the most substantial surface-exposed FyuA 
binding activity. Unfortunately, the surface-specific binding activity of antibodies from 
subclone 5E7.22 diminished substantially, to the level of a small shoulder, while being 
cultured in the subcloning process (Figure B-4B). Despite the diminished levels of 
bacterial cell surface binding, subclone 5E7.22 was injected into the peritoneal cavity of a 
BALB/c mouse to generate ascites fluid, highly concentrated in 5E7.22 monoclonal 
antibody.  
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Figure B-4. Screening hybridoma supernatants for monoclonal antibodies specific 
for surface-exposed domains of FyuA.  Histogram overlays of antibody binding as 
assessed by flow cytometry. UPEC strains 536 and 536ΔfyuA were cultured under iron-
limitation by the addition of 200 µM 2’2-dipyridyl and incubated with the FyuA-specific 
mAb (5E7.22), followed by a secondary antibody conjugated to FITC. Shaded area 
represents a control E. coli strain unable to express FyuA (536ΔfyuA), and the unshaded 
area denotes antibody binding to wild type E. coli. Initial 5E7.22 mAb binding activity 
(A) is compared to its binding activity at the time of ascites preparation (B).  
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Passive protection by FyuA-specific monoclonal antibodies (5E7.22) 
 Ascites fluid generated in BALB/c mice with hybridoma subclone 5E7.22 was 
harvested and used to passively immunize naïve six-to-eight week old female CBA/J 
mice. After 16 h, passively immunized mice were challenged with UPEC, either 
transurethrally, as an experimental model of UTI (Figure B-5A), or intravascularly, as an 
experimental model of system infection (Figure B-5A). Mice passively immunized with 
5E7.22 were not significantly protected from experimental challenge with UPEC in either 
experimental infection model (Figure B-5). 
 
Figure B-5. Monoclonal antibody 5E7.22 fails to protect CBA/J mice from 
experimental UTI or bacteremia. Six-to-eight week old female CBA/J mice were 
injected intraperitoneally with 200 µl of 5E7.22 ascites fluid (5E7) or PBS (PBS). After 
16 h, passively immunized mice were inoculated intraurethrally with 1 × 108 CFU UPEC 
536 (A) or intravascularly with 1 × 107 CFU UPEC 536 (B). Mice were euthanized 48 h 
(A) or 24 h (B) after UPEC inoculation and organs removed. Organs were homogenized 
in 3 ml PBS and plated onto LB agar to enumerate CFU/g tissue. Bars represent the 
median for each group and the dashed-line indicates the limit of detection for the assay 
(100 CFU/g tissue). Statistical significance was determined by a two-tailed Mann-
Whitney test, and each experimental group contained ten mice. 
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Monoclonal antibody levels in the urine and serum of passively immunized mice 
 To determine if IgG antibodies injected into the peritoneal cavity of naïve mice 
could be detected in the urine and serum after 16 h, individual urine and serum samples 
were collected from 10 mice before intraperitoneal injection with 5E7.22 ascites fluid or 
PBS, and then 16 h following. FyuA-specific IgG in the urine and serum was quantified 
by ELISA. Significant levels of FyuA-specific IgG was detected in the serum of mice 16 
h after intraperitoneal injection with 5E7.22 ascites fluid (5E7), as compared to PBS-
injected control mice (PBS), however no significant difference was observed in the urine 
(Figure B-6).  
 
Figure B-6. Monoclonal antibody levels in the urine and serum of passively 
immunized mice. Six-to-eight week old female CBA/J mice were passively immunized 
with either 5E7.22 ascites fluid (5E7) or PBS (PBS) by intraperitoneal injection. Serum 
and urine samples were individually collected prior to passive immunization (PRE), and 
again 16 h following (POST). FyuA-specific IgG was quantified by ELISA and 
significance was determined by a two-tailed Mann-Whitney test. Each group contained 
ten mice. 
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Appendix C. UPEC mutant 536ΔfyuA cannot import yersiniabactin 
To confirm that UPEC mutant 536ΔfyuA could not import yersiniabactin, we 
evaluated its growth on specific iron sources using an iron source utilization assay as 
described (217). PBS washed bacterial suspensions of 536ΔfyuA-pGENempty (Figure C-
1A) or 536ΔfyuA-pGENp-nativefyuA (Figure C-1B) were added to molten sorbitol-
MacConkey agar containing 350 µM 2’2-Dipyridyl to ∼5 × 104 CFU/ml. Wells (∼8-mm 
diameter) were punched into solidified plates using the ends of pipette tips, and 80 µl of 
an iron source was added to each well. Iron sources included 100 µM FeCl2, the culture 
supernatant from a UPEC mutant that only produces yersiniabactin (536ΔentF), or the 
supernatant from a UPEC mutant that only produces enterobactin and salmochelin 
(536ΔybtS). Siderophore donor strains were cultured overnight with 100 µM 2’2-
Dipyridyl to induce siderophore synthesis and supernatants were filter-sterilized and 
concentrated 10-fold using a vacuum centrifuge. Plates were imaged and the diameter of 
growth surrounding each well was measured after 72 h at 37°C.  
As expected, the UPEC 536ΔfyuA mutant could grow when FeCl2 or the 
supernatant from 536ΔybtS was provided as an iron source, but could not grow using the 
supernatant from a ΔentF536 mutant (Figure C-1A). The defect in yersiniabactin use could 
be complemented by expression of fyuA off of its native promoter in trans (Figure C-1B). 
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Figure C-1. UPEC mutant 536ΔfyuA cannot import yersiniabactin. Growth of the E. 
coli 536ΔfyuA mutant carrying empty pGEN vector (A) or pGEN-pnativefyuA (B) around 
wells containing 100 µM FeCl2 (top), the concentrated supernatant from a UPEC mutant 
only able to siderophores enterobactin and salmochelin (536ΔybtS) (ybtS-right), or the 
supernatant of a UPEC mutant only able to produce the siderophore yersiniabactin 
(536ΔentF) (entF-left). Bars indicate zones of growth. 
 
 
Author’s Note: Data in Appendix C is modified from the previously published research article: 
Garcia EC, Brumbaugh AR and Mobley HLT. Redundancy and Specificity of Escherichia coli 
Iron Acquisition Systems During Urinary Tract Infection. 2011. Infect Immun 79:1225-1235 
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Appendix D. Orphan receptor IreA does not contribute to UPEC fitness during UTI 
 To determine if the Fur-regulated orphan receptor and vaccine candidate IreA 
contributes to UPEC fitness during UTI, an isogenic mutant CFT073ΔireA was tested in 
a murine coinfection model. At 48 hpi, the CFT073ΔireA mutant was recovered at levels 
indistinguishable from wild type CFT073, from the bladder and kidneys (Figure D-1), 
indicating that ireA does not significantly contribute to UPEC fitness in the urinary tract.  
 
 
Figure D-1. IreA does not significantly contribute to UPEC fitness during UTI. Ten 
female CBA/J mice were transurethrally inoculated with a 1:1 mixture of E. coli CFT073 and 
E. coli CFT073ΔireA::kan (1 × 108 total CFU/mouse) and collonization was measured 48 
hpi. Competitive indices were calculated by dividing the fraction of the mutant in the output 
(CFU/g tissue) by the fraction of the mutant in the input (CFU/ml inoculum). Bars represent 
the median of value for each group and the dashed line indicates the theoretical median of 
zero. One mouse succumbed to the infection before being euthanized and is not included in 
the data. Significance was determined by Wilcoxon signed rank test with a theroretical 
median of zero. 
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Appendix E. Supplementary data from 2012 UHS E. coli UTI sample collection 
Antimicrobial resistance profile of UHS E. coli cystitis isolates 
 The antibiotic resistance profile of 38 E. coli strains isolated from the urine of 
women with cystits at the University of Michigan University Health Services clinic in 
Ann Arbor, MI, during the spring of 2012 as determined by a Vitek2 Compact System 
(Table E-1). Notably, the antibiotic resistance rates of E. coli cystitis isolates from the 
UHS are lower than those documented at the UM Hospital during the same year (2012):  
Ampicillin (N =1263)  S, 605 (48%) I, 44 (3%) R, 614 (49%) 
Ciprofloxacin (N =1263)  S, 917 (73%) I, 0 (0%) R, 338 (27%) 
TMP-SMX (N =1254)  S, 911 (73%) I, 0 (0%) R, 344 (27%) 
 
Table E-1. Antimicrobial resistance profile of UHS E. coli cystitis 
isolates determined by a Vitek2 Compact System (38 isolates) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial Agent Resistant N (%) Intermediate N (%) 
Amoxicillin/Clavulanic Acid 2 (5.1) 2 (5.1) 
Ampicillin 12 (30.8) 0 (0) 
Aztreonam 0 (0) 0 (0) 
Cefalotin 4 (10.2) 6 (15.4) 
Cefazolin 2 (5.1) 1 (2.6) 
Cefepime 0 (0) 0 (0) 
Cefoxitin 2 (5.1) 1 (2.6) 
Cefpodoxime 0 (0) 0 (0) 
Cefuroxime 1 (2.6) 0 (0) 
Cefuroxime axetil 1 (2.6) 1 (2.6) 
Ciprofloxacin 3 (7.7) 0 (0) 
Gentamicin 2 (5.1) 0 (0) 
Levofloxacin 3 (7.7) 0 (0) 
Nitrofurantoin 1 (2.6) 2 (5.1) 
Norfloxacin 3 (7.7) 0 (0) 
Tetracycline 7 (17.9) 0 (0) 
Tobramycin 3 (7.7) 0 (0) 
TMP-SMX 6 (15.3) 0 (0) 
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Orientation of the type 1 fimbrial promoter in UHS E. coli isolates during cystitis 
 Type 1 fimbria expression is regulated by a promoter on a 314 bp invertable 
element upstream of the gene fimA, a gene encoding the major structural subunit of type 1 
fimbria. As an indicator of type 1 fimbriae expression during human cystitis, the 
orientation of the fim invertable element was determined from the genomic DNA of E. 
coli isolated and immediately stabilized from the urine of women with uncomplicated 
cystitis, using an Invertable Element (IE) PCR-based assay (Figure E-1) (218). 
Surprisingly, the orientation of the fim promoter varied between patient isolates, as the 
promoter was in the ‘ON’ orientation in 6 isolates, in the ‘OFF’ orientation in 13 isolates, 
and in a ‘MIXED’ orientation in 3 isolates (Figure E-1B).  
 
Figure E-1. Orientation of the fim promoter from E. coli directly stabilized from the 
urine of women with uncomplicated cystitis. A diagram of the invertible element (IE) 
PCR-based type 1 fimbriae assay, modified from Hagan and colleagues (42) (A). The IE 
is in gray and an arrow indicated the orientation of the fim promoter (P). Black bars 
indicate the expected fragment sizes following PCR and asymmetrical digestion with 
SnaBI. CFT073 strains with mutations preventing IE switching are shown locked in the 
“phase-on” (L-ON) or “phase-off” (L-OFF) orientation. The orientation of the fim 
promoter in E. coli isolated from the urine of women with uncomplicated cystitis (HM01- 
HM82) (B). Molecular mass standard base sizes are indicated.  
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FyuA-specific serum IgG from adults with or without a history of UTI 
 To determine if UPEC-reactive serum antibodies correlate with patient UTI 
history, we assessed the reactivity of patient serum to individual UPEC iron receptors by 
ELISA. Serum samples collected from women at the UHS were evaluated for serum IgG 
specific for iron receptors: Hma, IroN, IutA, IreA, FitA, and FyuA. Although all 
individuals had low levels of serum IgG specific to UPEC iron receptors, no correlation 
between antigen-reactive antibody levels and UTI history was found (data not shown). 
Serum from healthy adult males, aged 18-35, was used as a control for non-UTI induced 
UPEC-specific serum IgG, and FyuA-specific reactivity was evaluated. No significant 
difference was found between the FyuA-specific serum IgG levels between men or 
women with no history of UTI, and women with recurrent UTI, supporting data 
suggesting the bladder is an immune-privileged body site (194)(Figure E-2). 
 
Figure E-2. FyuA-specific serum IgG reactivity of men and women. Serum samples 
from eight women with no history of UTI, eight women with recurrent UTI, and eight 
healthy men were probed for FyuA-specific IgG by indirect ELISA. Significance was 
determined by a two-tailed Mann-Whitney test. 
 
  
Men
0.0
0.2
0.4
0.6
0.8
A
bs
or
ba
nc
e 4
50
 n
m
Women
n.s.
n.s.
RecurrentNo History
 127 
 
 
REFERENCES 
 
 
 
  
 128 
1. Foxman B. 2010. The epidemiology of urinary tract infection. Nat Rev Urol 
7:653-660. 
2. Foxman B, Brown P. 2003. Epidemiology of urinary tract infections: 
transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 
17:227-241. 
3. Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, Tallman P, Marsh 
JV, Spear S, Sobel JD, Marty MJ, Marrs CF. 2000. Risk factors for second 
urinary tract infection among college women. American journal of epidemiology 
151:1194-1205. 
4. DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2008. 2006 National 
Hospital Discharge Survey. Natl Health Stat Report:1-20. 
5. Litwin MS, Saigal CS, Yano EM, Avila C, Geschwind SA, Hanley JM, Joyce 
GF, Madison R, Pace J, Polich SM, Wang M. 2005. Urologic diseases in 
America Project: analytical methods and principal findings. The Journal of 
Urology 173:933-937. 
6. Muhldorfer I. 2001. Emerging bacterial pathogens. Preface. Contrib Microbiol 
8:XI-XIV. 
7. Mehnert-Kay SA. 2005. Diagnosis and management of uncomplicated urinary 
tract infections. Am Fam Physician 72:451-456. 
8. Foxman B. 1990. Recurring urinary tract infection: incidence and risk factors. 
Am J Public Health 80:331-333. 
9. Zhang L, Foxman B. 2003. Molecular epidemiology of Escherichia coli 
mediated urinary tract infections. Front Biosci 8:e235-244. 
10. Johnson JR, Russo TA. 2002. Uropathogenic Escherichia coli as agents of 
diverse non-urinary tract extraintestinal infections. The Journal of infectious 
diseases 186:859-864. 
11. Wiles TJ, Kulesus RR, Mulvey MA. 2008. Origins and virulence mechanisms of 
uropathogenic Escherichia coli. Exp Mol Pathol 85:11-19. 
12. Welch RA, Burland V, Plunkett G, 3rd, Redford P, Roesch P, Rasko D, 
Buckles EL, Liou SR, Boutin A, Hackett J, Stroud D, Mayhew GF, Rose DJ, 
Zhou S, Schwartz DC, Perna NT, Mobley HL, Donnenberg MS, Blattner FR. 
2002. Extensive mosaic structure revealed by the complete genome sequence of 
uropathogenic Escherichia coli. P Natl Acad Sci USA 99:17020-17024. 
13. Wright KJ, Hultgren SJ. 2006. Sticky fibers and uropathogenesis: bacterial 
adhesins in the urinary tract. Future Microbiol 1:75-87. 
 129 
14. Kodner CM, Thomas Gupton EK. 2010. Recurrent urinary tract infections in 
women: diagnosis and management. American family physician 82:638-643. 
15. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, 
Nicolle LE, Raz R, Schaeffer AJ, Soper DE. 2011. International clinical 
practice guidelines for the treatment of acute uncomplicated cystitis and 
pyelonephritis in women: a 2010 update by the infectious diseases society of 
america and the European society for microbiology and infectious diseases. Clin 
Infect Dis 52:e103-120. 
16. Moura A, Nicolau A, Hooton T, Azeredo J. 2009. Antibiotherapy and 
pathogenesis of uncomplicated UTI: difficult relationships. Journal of applied 
microbiology 106:1779-1791. 
17. Foxman B, Ki M, Brown P. 2007. Antibiotic resistance and pyelonephritis. Clin 
Infect Dis 45:281-283. 
18. Karaca Y, Coplu N, Gozalan A, Oncul O, Citil BE, Esen B. 2005. Co-
trimoxazole and quinolone resistance in Escherichia coli isolated from urinary 
tract infections over the last 10 years. International journal of antimicrobial agents 
26:75-77. 
19. Gupta K, Hooton TM, Stamm WE. 2001. Increasing antimicrobial resistance 
and the management of uncomplicated community-acquired urinary tract 
infections. Annals of internal medicine 135:41-50. 
20. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Palatnik 
LP, Johnson J, Noreddin A, Harding GK, Nicolle LE, Hoban DJ. 2005. 
Antibiotic resistance in outpatient urinary isolates: final results from the North 
American Urinary Tract Infection Collaborative Alliance (NAUTICA). 
International journal of antimicrobial agents 26:380-388. 
21. Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG. 2006. 
Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are 
frequently multidrug resistant: results from the North American Urinary Tract 
Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents 
Chemother (Bethesda) 50:2251-2254. 
22. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. 
2009. The ARESC study: an international survey on the antimicrobial resistance 
of pathogens involved in uncomplicated urinary tract infections. International 
journal of antimicrobial agents 34:407-413. 
23. MacDonald TM, Beardon PH, McGilchrist MM, Duncan ID, McKendrick 
AD, McDevitt DG. 1993. The risks of symptomatic vaginal candidiasis after oral 
antibiotic therapy. Q J Med 86:419-424. 
 130 
24. Bartlett JG. 2006. Narrative review: the new epidemic of Clostridium difficile-
associated enteric disease. Annals of internal medicine 145:758-764. 
25. Dethlefsen L, Huse S, Sogin ML, Relman DA. 2008. The pervasive effects of an 
antibiotic on the human gut microbiota, as revealed by deep 16S rRNA 
sequencing. PLoS Biol 6:e280. 
26. Van Eldere J, Mera RM, Miller LA, Poupard JA, Amrine-Madsen H. 2007. 
Risk factors for development of multiple-class resistance to Streptococcus 
pneumoniae Strains in Belgium over a 10-year period: antimicrobial consumption, 
population density, and geographic location. Antimicrob Agents Chemother 
(Bethesda) 51:3491-3497. 
27. Billips BK, Schaeffer AJ, Klumpp DJ. 2008. Molecular basis of uropathogenic 
Escherichia coli evasion of the innate immune response in the bladder. Infection 
and Immunity 76:3891-3900. 
28. Sivick KE, Schaller MA, Smith SN, Mobley HL. 2010. The innate immune 
response to uropathogenic Escherichia coli involves IL-17A in a murine model of 
urinary tract infection. Journal of immunology 184:2065-2075. 
29. Kruze D, Holzbecher K, Andrial M, Bossart W. 1989. Urinary antibody 
response after immunisation with a vaccine against urinary tract infection. 
Urological research 17:361-366. 
30. Kruze D, Biro K, Holzbecher K, Andrial M, Bossart W. 1992. Protection by a 
polyvalent vaccine against challenge infection and pyelonephritis. Urological 
research 20:177-181. 
31. Uehling DT, James LJ, Hopkins WJ, Balish E. 1991. Immunization against 
urinary tract infection with a multi-valent vaginal vaccine. The Journal of Urology 
146:223-226. 
32. Alteri CJ, Hagan EC, Sivick KE, Smith SN, Mobley HL. 2009. Mucosal 
immunization with iron receptor antigens protects against urinary tract infection. 
PLoS Pathog 5:e1000586. 
33. Thumbikat P, Waltenbaugh C, Schaeffer AJ, Klumpp DJ. 2006. Antigen-
specific responses accelerate bacterial clearance in the bladder. Journal of 
immunology 176:3080-3086. 
34. Sivick KE, Mobley HL. 2009. An "omics" approach to uropathogenic 
Escherichia coli vaccinology. Trends Microbiol 17:431-432. 
35. Lycke N. 2005. Targeted vaccine adjuvants based on modified cholera toxin. Curr 
Mol Med 5:591-597. 
 131 
36. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. 2003. Mucosal 
immunisation and adjuvants: a brief overview of recent advances and challenges. 
Vaccine 21 Suppl 2:S89-95. 
37. Scavone P, Rial A, Umpierrez A, Chabalgoity A, Zunino P. 2009. Effects of 
the administration of cholera toxin as a mucosal adjuvant on the immune and 
protective response induced by Proteus mirabilis MrpA fimbrial protein in the 
urinary tract. Microbiol Immunol 53:233-240. 
38. Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, DeLisa MP, 
Putnam D. 2010. Delivery of foreign antigens by engineered outer membrane 
vesicle vaccines. P Natl Acad Sci USA 107:3099-3104. 
39. McLachlan JB, Shelburne CP, Hart JP, Pizzo SV, Goyal R, Brooking-Dixon 
R, Staats HF, Abraham SN. 2008. Mast cell activators: a new class of highly 
effective vaccine adjuvants. Nat Med 14:536-541. 
40. Hung CS, Dodson KW, Hultgren SJ. 2009. A murine model of urinary tract 
infection. Nat Protoc 4:1230-1243. 
41. Fox JG. 2007. The mouse in biomedical research, 2nd ed. Elsevier, Amsterdam ; 
Boston. 
42. Hagan EC, Lloyd AL, Rasko DA, Faerber GJ, Mobley HL. 2010. Escherichia 
coli global gene expression in urine from women with urinary tract infection. 
PLoS Pathogens 6:e1001187. 
43. Whitfield C. 2006. Biosynthesis and assembly of capsular polysaccharides in 
Escherichia coli. Annu Rev Biochem 75:39-68. 
44. Buckles EL, Wang X, Lane MC, Lockatell CV, Johnson DE, Rasko DA, 
Mobley HL, Donnenberg MS. 2009. Role of the K2 capsule in Escherichia coli 
urinary tract infection and serum resistance. The Journal of infectious diseases 
199:1689-1697. 
45. Russo TA, Beanan JM, Olson R, MacDonald U, Cope JJ. 2009. Capsular 
polysaccharide and the O-specific antigen impede antibody binding: a potential 
obstacle for the successful development of an extraintestinal pathogenic 
Escherichia coli vaccine. Vaccine 27:388-395. 
46. Uehling DT, Wolf L. 1969. Enhancement of the bladder defense mechanism by 
immunization. Invest Urol 6:520-526. 
47. Kaijser B, Ahlstedt S. 1977. Protective capacity of antibodies against 
Escherichia coli and K antigens. Infection and Immunity 17:286-289. 
48. Kumar V, Ganguly N, Joshi K, Mittal R, Harjai K, Chhibber S, Sharma S. 
2005. Protective efficacy and immunogenicity of Escherichia coli K13 diphtheria 
 132 
toxoid conjugate against experimental ascending pyelonephritis. Medical 
microbiology and immunology 194:211-217. 
49. Kaijser B, Larsson P, Olling S, Schneerson R. 1983. Protection against acute, 
ascending pyelonephritis caused by Escherichia coli in rats, using isolated 
capsular antigen conjugated to bovine serum albumin. Infection and Immunity 
39:142-146. 
50. Kaijser B, Larsson P, Nimmich W, Soderstrom T. 1983. Antibodies to 
Escherichia coli K and O antigens in protection against acute pyelonephritis. Prog 
Allergy 33:275-288. 
51. Whitfield C, Roberts IS. 1999. Structure, assembly and regulation of expression 
of capsules in Escherichia coli. Molecular microbiology 31:1307-1319. 
52. Johnson JR. 1991. Virulence factors in Escherichia coli urinary tract infection. 
Clin Microbiol Rev 4:80-128. 
53. Hoffman S, Sorkin BC, White PC, Brackenbury R, Mailhammer R, 
Rutishauser U, Cunningham BA, Edelman GM. 1982. Chemical 
characterization of a neural cell adhesion molecule purified from embryonic brain 
membranes. The Journal of biological chemistry 257:7720-7729. 
54. Jann K, Jann B. 1987. Polysaccharide antigens of Escherichia coli. Reviews of 
infectious diseases 9 Suppl 5:S517-526. 
55. Vann WF, Schmidt MA, Jann B, Jann K. 1981. The structure of the capsular 
polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 
010:K5:H4. A polymer similar to desulfo-heparin. Eur J Biochem 116:359-364. 
56. Rappuoli R, Bagnoli F. 2011. Vaccine design : innovative approaches and novel 
strategies. Caister Academic, Norfolk, UK. 
57. Johnson JR, Kuskowski MA, Gajewski A, Soto S, Horcajada JP, Jimenez de 
Anta MT, Vila J. 2005. Extended virulence genotypes and phylogenetic 
background of Escherichia coli isolates from patients with cystitis, pyelonephritis, 
or prostatitis. The Journal of infectious diseases 191:46-50. 
58. Grischke EM, Ruttgers H. 1987. Treatment of bacterial infections of the female 
urinary tract by immunization of the patients. Urol Int 42:338-341. 
59. Knuf M, Habermehl P, Faber J, Bock HL, Sanger R, Bogaerts H, Clemens R, 
Schuind A, du Prel JB, Schmitt HJ. 2006. Assessment of nine candidate DTP-
vaccines with reduced amount of antigen and/or without adjuvant as a fourth 
(booster-) dose in the second year of life. Vaccine 24:5627-5636. 
 133 
60. Mestecky J. 1987. The common mucosal immune system and current strategies 
for induction of immune responses in external secretions. J Clin Immunol 7:265-
276. 
61. Uehling DT, Hopkins WJ, Balish E, Xing Y, Heisey DM. 1997. Vaginal 
mucosal immunization for recurrent urinary tract infection: phase II clinical trial. 
The Journal of Urology 157:2049-2052. 
62. Uehling DT, Hopkins WJ, Beierle LM, Kryger JV, Heisey DM. 2001. Vaginal 
mucosal immunization for recurrent urinary tract infection: extended phase II 
clinical trial. The Journal of infectious diseases 183 Suppl 1:S81-83. 
63. Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. 2003. 
Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. The 
Journal of Urology 170:867-869. 
64. Hopkins W, Elkahwaji J, Beierle L, Leverson G, Uehling D. 2007. Vaginal 
Mucosal Vaccine for Recurrent Urinary Tract Infections in Women: Results of a 
Phase 2 Clinical Trial. The Journal of Urology 177:1349-1353. 
65. Frey C, Obolensky W, Wyss H. 1986. Treatment of recurrent urinary tract 
infections: efficacy of an orally administered biological response modifier. Urol 
Int 41:444-446. 
66. Hachen HJ. 1990. Oral immunotherapy in paraplegic patients with chronic 
urinary tract infections: a double-blind, placebo-controlled trial. The Journal of 
Urology 143:759-762; discussion 762-753. 
67. Schulman CC, Corbusier A, Michiels H, Taenzer HJ. 1993. Oral 
immunotherapy of recurrent urinary tract infections: a double-blind placebo-
controlled multicenter study. The Journal of Urology 150:917-921. 
68. Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC. 
2005. A long-term, multicenter, double-blind study of an Escherichia coli extract 
(OM-89) in female patients with recurrent urinary tract infections. Eur Urol 
47:542-548; discussion 548. 
69. Kim KS, Kim JY, Jeong IG, Paick JS, Son H, Lim DJ, Shim HB, Park WH, 
Jung HC, Choo MS. 2010. A prospective multi-center trial of Escherichia coli 
extract for the prophylactic treatment of patients with chronically recurrent 
cystitis. J Korean Med Sci 25:435-439. 
70. Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. 2002. Prevention of 
recurrent urinary tract infections with immuno-active E. coli fractions: a meta-
analysis of five placebo-controlled double-blind studies. International journal of 
antimicrobial agents 19:451-456. 
 134 
71. Koukalova D, Krocova Z, Vitek P, Macela A, Hajek V. 1999. 
[Immunostimulatory activity of the vaccine used in the treatment of recurrent 
urinary infections. II]. Bratisl Lek Listy 100:215-217. 
72. Koukalova D, Reif R, Hajek V, Mucha Z, Vesely J, Viktorinova M, Lochman 
I. 1999. [Immunomodulation of recurrent urinary tract infections with Urvakol 
vaccine]. Bratisl Lek Listy 100:246-251. 
73. Marinova S, Nenkov P, Markova R, Nikolaeva S, Kostadinova R, Mitov I, 
Vretenarska M. 2005. Cellular and humoral systemic and mucosal immune 
responses stimulated by an oral polybacterial immunomodulator in patients with 
chronic urinary tract infections. Int J Immunopathol Pharmacol 18:457-473. 
74. Uehling DT, Hopkins WJ, Dahmer LA, Balish E. 1994. Phase I clinical trial of 
vaginal mucosal immunization for recurrent urinary tract infection. The Journal of 
Urology 152:2308-2311. 
75. Uehling DT, Hopkins WJ, James LJ, Balish E. 1994. Vaginal immunization of 
monkeys against urinary tract infection with a multi-strain vaccine. The Journal of 
Urology 151:214-216. 
76. Russo TA, Beanan JM, Olson R, Genagon SA, MacDonald U, Cope JJ, 
Davidson BA, Johnston B, Johnson JR. 2007. A killed, genetically engineered 
derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine 
candidate. Vaccine 25:3859-3870. 
77. Billips BK, Yaggie RE, Cashy JP, Schaeffer AJ, Klumpp DJ. 2009. A live-
attenuated vaccine for the treatment of urinary tract infection by uropathogenic 
Escherichia coli. J Infect Dis 200:263-272. 
78. Spurbeck RR, Stapleton AE, Johnson JR, Walk ST, Hooton TM, Mobley 
HL. 2011. Fimbrial Profiles Predict Virulence of Uropathogenic E. coli Strains: 
Contribution of Ygi and Yad Fimbriae. Infection and Immunity. 
79. Thankavel K, Madison B, Ikeda T, Malaviya R, Shah AH, Arumugam PM, 
Abraham SN. 1997. Localization of a domain in the FimH adhesin of 
Escherichia coli type 1 fimbriae capable of receptor recognition and use of a 
domain-specific antibody to confer protection against experimental urinary tract 
infection. J Clin Invest 100:1123-1136. 
80. Lane MC, Mobley HL. 2007. Role of P-fimbrial-mediated adherence in 
pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the 
mammalian kidney. Kidney Int 72:19-25. 
81. O'Hanley P, Lark D, Falkow S, Schoolnik G. 1985. Molecular basis of 
Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal 
pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse 
model of human pyelonephritis. The Journal of clinical investigation 75:347-360. 
 135 
82. Roberts JA, Hardaway K, Kaack B, Fussell EN, Baskin G. 1984. Prevention 
of pyelonephritis by immunization with P-fimbriae. The Journal of Urology 
131:602-607. 
83. Roberts JA, Kaack MB, Baskin G, Chapman MR, Hunstad DA, Pinkner JS, 
Hultgren SJ. 2004. Antibody responses and protection from pyelonephritis 
following vaccination with purified Escherichia coli PapDG protein. J Urol 
171:1682-1685. 
84. Carnoy C, Moseley SL. 1997. Mutational analysis of receptor binding mediated 
by the Dr family of Escherichia coli adhesins. Molecular microbiology 23:365-
379. 
85. Westerlund B, Kuusela P, Risteli J, Risteli L, Vartio T, Rauvala H, Virkola 
R, Korhonen TK. 1989. The O75X adhesin of uropathogenic Escherichia coli is 
a type IV collagen-binding protein. Molecular microbiology 3:329-337. 
86. Goluszko P, Moseley SL, Truong LD, Kaul A, Williford JR, Selvarangan R, 
Nowicki S, Nowicki B. 1997. Development of experimental model of chronic 
pyelonephritis with Escherichia coli O75:K5:H-bearing Dr fimbriae: mutation in 
the dra region prevented tubulointerstitial nephritis. The Journal of clinical 
investigation 99:1662-1672. 
87. Goluszko P, Goluszko E, Nowicki B, Nowicki S, Popov V, Wang HQ. 2005. 
Vaccination with purified Dr Fimbriae reduces mortality associated with chronic 
urinary tract infection due to Escherichia coli bearing Dr adhesin. Infect Immun 
73:627-631. 
88. Zhou G, Mo WJ, Sebbel P, Min G, Neubert TA, Glockshuber R, Wu XR, 
Sun TT, Kong XP. 2001. Uroplakin Ia is the urothelial receptor for 
uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci 
114:4095-4103. 
89. Connell I, Agace W, Klemm P, Schembri M, Marild S, Svanborg C. 1996. 
Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary 
tract. P Natl Acad Sci USA 93:9827-9832. 
90. Iwahi T, Abe Y, Nakao M, Imada A, Tsuchiya K. 1983. Role of type 1 
fimbriae in the pathogenesis of ascending urinary tract infection induced by 
escherichia coli in mice. Infection and Immunity 39:1307-1315. 
91. Aronson M, Medalia O, Schori L, Mirelman D, Sharon N, Ofek I. 1979. 
Prevention of colonization of the urinary tract of mice with Escherichia coli by 
blocking of bacterial adherence with methyl alpha-D-mannopyranoside. The 
Journal of infectious diseases 139:329-332. 
92. Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein 
J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. 1997. Prevention of 
 136 
mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. 
Science 276:607-611. 
93. Langermann S, Mollby R, Burlein JE, Palaszynski SR, Auguste CG, DeFusco 
A, Strouse R, Schenerman MA, Hultgren SJ, Pinkner JS, Winberg J, 
Guldevall L, Soderhall M, Ishikawa K, Normark S, Koenig S. 2000. 
Vaccination with FimH adhesin protects cynomolgus monkeys from colonization 
and infection by uropathogenic Escherichia coli. The Journal of infectious 
diseases 181:774-778. 
94. Langermann S, Ballou WR, Jr. 2001. Vaccination utilizing the FimCH complex 
as a strategy to prevent Escherichia coli urinary tract infections. J Infect Dis 183 
Suppl 1:S84-86. 
95. Meiland R, Geerlings SE, Langermann S, Brouwer EC, Coenjaerts FE, 
Hoepelman AI. 2004. Fimch antiserum inhibits the adherence of Escherichia coli 
to cells collected by voided urine specimens of diabetic women. J Urol 171:1589-
1593. 
96. 2002. Medimmune, Inc.  Annual Report. 
97. Personal correspondence with the MedImmune Medical Affairs Department, 
January 9th 2012. 
98. Lim JK, Gunther NWt, Zhao H, Johnson DE, Keay SK, Mobley HL. 1998. In 
vivo phase variation of Escherichia coli type 1 fimbrial genes in women with 
urinary tract infection. Infection and Immunity 66:3303-3310. 
99. Eisenstein BI. 1981. Phase variation of type 1 fimbriae in Escherichia coli is 
under transcriptional control. Science 214:337-339. 
100. Nowicki B, Rhen M, Vaisanen-Rhen V, Pere A, Korhonen TK. 1984. 
Immunofluorescence study of fimbrial phase variation in Escherichia coli KS71. 
Journal of bacteriology 160:691-695. 
101. Tchesnokova V, Aprikian P, Kisiela D, Gowey S, Korotkova N, Thomas W, 
Sokurenko E. 2011. Type 1 fimbrial adhesin FimH elicits immune response 
which enhances cell adhesion of Escherichia coli. Infection and Immunity. 
102. O'Hanley P, Lalonde G, Ji G. 1991. Alpha-hemolysin contributes to the 
pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: 
efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c 
mouse model of pyelonephritis. Infect Immun 59:1153-1161. 
103. Nielubowicz GR, Mobley HL. 2010. Host-pathogen interactions in urinary tract 
infection. Nat Rev Urol 7:430-441. 
 137 
104. Rippere-Lampe KE, Lang M, Ceri H, Olson M, Lockman HA, O'Brien AD. 
2001. Cytotoxic necrotizing factor type 1-positive Escherichia coli causes 
increased inflammation and tissue damage to the prostate in a rat prostatitis 
model. Infection and Immunity 69:6515-6519. 
105. Smith YC, Rasmussen SB, Grande KK, Conran RM, O'Brien AD. 2008. 
Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the 
uroepithelium and hemorrhage in bladder tissue within the first 24 hours after 
intraurethral inoculation of mice. Infection and Immunity 76:2978-2990. 
106. Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, Pastorello 
I, Corea VA, Torricelli G, Cartocci E, Savino S, Scarselli M, Dobrindt U, 
Hacker J, Tettelin H, Tallon LJ, Sullivan S, Wieler LH, Ewers C, Pickard D, 
Dougan G, Fontana MR, Rappuoli R, Pizza M, Serino L. 2010. Identification 
of protective and broadly conserved vaccine antigens from the genome of 
extraintestinal pathogenic Escherichia coli. P Natl Acad Sci USA 107:9072-9077. 
107. Torres AG, Redford P, Welch RA, Payne SM. 2001. TonB-dependent systems 
of uropathogenic Escherichia coli: aerobactin and heme transport and TonB are 
required for virulence in the mouse. Infection and Immunity 69:6179-6185. 
108. Chu BC, Garcia-Herrero A, Johanson TH, Krewulak KD, Lau CK, Peacock 
RS, Slavinskaya Z, Vogel HJ. 2010. Siderophore uptake in bacteria and the 
battle for iron with the host; a bird's eye view. Biometals 23:601-611. 
109. Snyder JA, Haugen BJ, Buckles EL, Lockatell CV, Johnson DE, Donnenberg 
MS, Welch RA, Mobley HL. 2004. Transcriptome of uropathogenic Escherichia 
coli during urinary tract infection. Infection and Immunity 72:6373-6381. 
110. Faraldo-Gomez JD, Sansom MS. 2003. Acquisition of siderophores in gram-
negative bacteria. Nature reviews. Molecular cell biology 4:105-116. 
111. Henderson JP, Crowley JR, Pinkner JS, Walker JN, Tsukayama P, Stamm 
WE, Hooton TM, Hultgren SJ. 2009. Quantitative metabolomics reveals an 
epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS 
pathogens 5:e1000305. 
112. Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Olson R, 
Wilding GE. 2003. The Siderophore receptor IroN of extraintestinal pathogenic 
Escherichia coli is a potential vaccine candidate. Infection and Immunity 
71:7164-7169. 
113. Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S. 
2007. Identification of candidates for a subunit vaccine against extraintestinal 
pathogenic Escherichia coli. Infection and Immunity 75:1916-1925. 
 138 
114. Carbonetti NH, Boonchai S, Parry SH, Vaisanen-Rhen V, Korhonen TK, 
Williams PH. 1986. Aerobactin-mediated iron uptake by Escherichia coli isolates 
from human extraintestinal infections. Infection and Immunity 51:966-968. 
115. Garcia EC, Brumbaugh AR, Mobley HL. 2011. Redundancy and specificity of 
Escherichia coli iron acquisition systems during urinary tract infection. Infection 
and Immunity 79:1225-1235. 
116. Watts RE, Totsika M, Challinor VL, Mabbett AN, Ulett GC, De Voss JJ, 
Schembri MA. 2012. Contribution of Siderophore Systems to Growth and 
Urinary Tract Colonization of Asymptomatic Bacteriuria Escherichia coli. 
Infection and Immunity 80:333-344. 
117. Wieser A, Romann E, Magistro G, Hoffmann C, Norenberg D, Weinert K, 
Schubert S. 2010. A multiepitope subunit vaccine conveys protection against 
extraintestinal pathogenic Escherichia coli in mice. Infection and Immunity 
78:3432-3442. 
118. Wieser A, Magistro G, Norenberg D, Hoffmann C, Schubert S. 2012. First 
multi-epitope subunit vaccine against extraintestinal pathogenic Escherichia coli 
delivered by a bacterial type-3 secretion system (T3SS). International journal of 
medical microbiology : IJMM 302:10-18. 
119. Brumbaugh AR, Smith SN, Mobley HL. 2013. Immunization with the 
yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model 
of urinary tract infection. Infect Immun 81:3309-3316. 
120. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. 
2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 
301:105-107. 
121. Rice JC, Peng T, Spence JS, Wang HQ, Goldblum RM, Corthesy B, Nowicki 
BJ. 2005. Pyelonephritic Escherichia coli expressing P fimbriae decrease immune 
response of the mouse kidney. Journal of the American Society of Nephrology : 
JASN 16:3583-3591. 
122. Cirl C, Wieser A, Yadav M, Duerr S, Schubert S, Fischer H, Stappert D, 
Wantia N, Rodriguez N, Wagner H, Svanborg C, Miethke T. 2008. 
Subversion of Toll-like receptor signaling by a unique family of bacterial 
Toll/interleukin-1 receptor domain-containing proteins. Nat Med 14:399-406. 
123. He Y, Xiang Z, Mobley HL. 2010. Vaxign: the first web-based vaccine design 
program for reverse vaccinology and applications for vaccine development. J 
Biomed Biotechnol 2010:297505. 
124. Schappert SM, Rechtsteiner EA. 2008. Ambulatory medical care utilization 
estimates for 2006. Natl Health Stat Report:1-29. 
 139 
125. Foxman B. 2002. Epidemiology of urinary tract infections: incidence, morbidity, 
and economic costs. Am J Med 113 Suppl 1A:5S-13S. 
126. Schappert SM, Rechtsteiner EA. 2011. Ambulatory medical care utilization 
estimates for 2007. Vital and health statistics. Series 13, Data from the National 
Health Survey:1-38. 
127. Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A. 2010. 
National Hospital Discharge Survey: 2007 summary. Natl Health Stat Report:1-
20, 24. 
128. Gordon KA, Jones RN, Groups SP. 2003. Susceptibility patterns of orally 
administered antimicrobials among urinary tract infection pathogens from 
hospitalized patients in North America: comparison report to Europe and Latin 
America. Results from the SENTRY Antimicrobial Surveillance Program (2000). 
Diagn Microbiol Infect Dis 45:295-301. 
129. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. 
2009. The ARESC study: an international survey on the antimicrobial resistance 
of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob 
Agents 34:407-413. 
130. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, 
Weshnoweski B, Johnson J, Noreddin A, Low DE, Karlowsky JA, Group N, 
Hoban DJ. 2006. Antibiotic resistance in Escherichia coli outpatient urinary 
isolates: final results from the North American Urinary Tract Infection 
Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 27:468-475. 
131. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, 
Fridkin SK, National Healthcare Safety Network T, Participating National 
Healthcare Safety Network F. 2008. NHSN annual update: antimicrobial-
resistant pathogens associated with healthcare-associated infections: annual 
summary of data reported to the National Healthcare Safety Network at the 
Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp 
Epidemiol 29:996-1011. 
132. Brumbaugh AR, Mobley HL. 2012. Preventing urinary tract infection: progress 
toward an effective Escherichia coli vaccine. Expert Rev Vaccines 11:663-676. 
133. Russo TA, Johnson JR. 2006. Extraintestinal isolates of Escherichia coli: 
identification and prospects for vaccine development. Expert Rev Vaccines 5:45-
54. 
134. Dobrindt U, Hacker J. 2008. Targeting virulence traits: potential strategies to 
combat extraintestinal pathogenic E. coli infections. Curr Opin Microbiol 11:409-
413. 
 140 
135. Nicolle LE, Committee* ACG. 2005. Complicated urinary tract infection in 
adults. The Canadian journal of infectious diseases & medical microbiology = 
Journal canadien des maladies infectieuses et de la microbiologie medicale / 
AMMI Canada 16:349-360. 
136. Giefing C, Meinke AL, Hanner M, Henics T, Bui MD, Gelbmann D, 
Lundberg U, Senn BM, Schunn M, Habel A, Henriques-Normark B, Ortqvist 
A, Kalin M, von Gabain A, Nagy E. 2008. Discovery of a novel class of highly 
conserved vaccine antigens using genomic scale antigenic fingerprinting of 
pneumococcus with human antibodies. J Exp Med 205:117-131. 
137. Lee SJ, Liang L, Juarez S, Nanton MR, Gondwe EN, Msefula CL, Kayala 
MA, Necchi F, Heath JN, Hart P, Tsolis RM, Heyderman RS, MacLennan 
CA, Felgner PL, Davies DH, McSorley SJ. 2012. Identification of a common 
immune signature in murine and human systemic Salmonellosis. Proc Natl Acad 
Sci U S A 109:4998-5003. 
138. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, 
Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, 
Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, 
Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason 
T, Tettelin H, Hood DW, Jeffries AC, Saunders NJ, Granoff DM, Venter JC, 
Moxon ER, Grandi G, Rappuoli R. 2000. Identification of vaccine candidates 
against serogroup B meningococcus by whole-genome sequencing. Science 
287:1816-1820. 
139. Lloyd AL, Rasko DA, Mobley HL. 2007. Defining genomic islands and 
uropathogen-specific genes in uropathogenic Escherichia coli. Journal of 
bacteriology 189:3532-3546. 
140. Chen SL, Hung CS, Xu J, Reigstad CS, Magrini V, Sabo A, Blasiar D, Bieri 
T, Meyer RR, Ozersky P, Armstrong JR, Fulton RS, Latreille JP, Spieth J, 
Hooton TM, Mardis ER, Hultgren SJ, Gordon JI. 2006. Identification of genes 
subject to positive selection in uropathogenic strains of Escherichia coli: a 
comparative genomics approach. P Natl Acad Sci USA 103:5977-5982. 
141. Bahrani-Mougeot FK, Buckles EL, Lockatell CV, Hebel JR, Johnson DE, 
Tang CM, Donnenberg MS. 2002. Type 1 fimbriae and extracellular 
polysaccharides are preeminent uropathogenic Escherichia coli virulence 
determinants in the murine urinary tract. Mol Microbiol 45:1079-1093. 
142. Hagan EC, Mobley HL. 2007. Uropathogenic Escherichia coli outer membrane 
antigens expressed during urinary tract infection. Infect Immun 75:3941-3949. 
143. Walters MS, Mobley HL. 2009. Identification of uropathogenic Escherichia coli 
surface proteins by shotgun proteomics. J Microbiol Methods 78:131-135. 
 141 
144. Alteri CJ, Mobley HL. 2007. Quantitative profile of the uropathogenic 
Escherichia coli outer membrane proteome during growth in human urine. Infect 
Immun 75:2679-2688. 
145. Vigil PD, Alteri CJ, Mobley HL. 2011. Identification of In Vivo-Induced 
Antigens Including an RTX Family Exoprotein Required for Uropathogenic 
Escherichia coli Virulence. Infection and Immunity 79:2335-2344. 
146. Alteri CJ, Hagan EC, Sivick KE, Smith SN, Mobley HL. 2009. Mucosal 
immunization with iron receptor antigens protects against urinary tract infection. 
PLoS Pathogens 5:e1000586. 
147. Hacker J, Knapp S, Goebel W. 1983. Spontaneous deletions and flanking 
regions of the chromosomally inherited hemolysin determinant of an Escherichia 
coli O6 strain. Journal of bacteriology 154:1145-1152. 
148. Mobley HL, Green DM, Trifillis AL, Johnson DE, Chippendale GR, 
Lockatell CV, Jones BD, Warren JW. 1990. Pyelonephritogenic Escherichia 
coli and killing of cultured human renal proximal tubular epithelial cells: role of 
hemolysin in some strains. Infection and Immunity 58:1281-1289. 
149. Johnson DE, Lockatell CV, Hall-Craigs M, Mobley HL, Warren JW. 1987. 
Uropathogenicity in rats and mice of Providencia stuartii from long-term 
catheterized patients. J Urol 138:632-635. 
150. R Development Core Team. 2011. R: A language and environment for statistical 
computing, 2.14.1 ed. R Foundation for Statistical Computing, Vienna, Austria. 
151. Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin Vaccine 
Immunol 17:1055-1065. 
152. Elgueta R, de Vries VC, Noelle RJ. 2010. The immortality of humoral 
immunity. Immunol Rev 236:139-150. 
153. Johnson JR, Johnston B, Kuskowski MA, Nougayrede JP, Oswald E. 2008. 
Molecular epidemiology and phylogenetic distribution of the Escherichia coli pks 
genomic island. J Clin Microbiol 46:3906-3911. 
154. Schubert S, Picard B, Gouriou S, Heesemann J, Denamur E. 2002. Yersinia 
high-pathogenicity island contributes to virulence in Escherichia coli causing 
extraintestinal infections. Infect Immun 70:5335-5337. 
155. Garcia EC, Brumbaugh AR, Mobley HL. 2011. Redundancy and Specificity of 
Escherichia coli Iron Acquisition Systems during Urinary Tract Infection. Infect 
Immun 79:1225-1235. 
 142 
156. Fetherston JD, Kirillina O, Bobrov AG, Paulley JT, Perry RD. 2010. The 
yersiniabactin transport system is critical for the pathogenesis of bubonic and 
pneumonic plague. Infect Immun 78:2045-2052. 
157. Lawlor MS, O'Connor C, Miller VL. 2007. Yersiniabactin is a virulence factor 
for Klebsiella pneumoniae during pulmonary infection. Infect Immun 75:1463-
1472. 
158. Spurbeck RR, Dinh PC, Jr., Walk ST, Stapleton AE, Hooton TM, Nolan LK, 
Kim KS, Johnson JR, Mobley HL. 2012. Escherichia coli isolates that carry vat, 
fyuA, chuA, and yfcV efficiently colonize the urinary tract. Infect Immun 
80:4115-4122. 
159. Howard SJ, Hopwood S, Davies SC. 2014. Antimicrobial resistance: a global 
challenge. Sci Transl Med 6:236ed210. 
160. Jones RN. 2010. Microbial etiologies of hospital-acquired bacterial pneumonia 
and ventilator-associated bacterial pneumonia. Clin Infect Dis 51 Suppl 1:S81-
87. 
161. Miajlovic H, Smith SG. 2014. Bacterial self-defence: how Escherichia coli 
evades serum killing. FEMS Microbiol Lett 354:1-9. 
162. 2014. Antimicrobial resistance: global report on surveillance, p. 256. World 
Health Organization. 
163. Moayednia R, Shokri D, Mobasherizadeh S, Baradaran A, Fatemi SM, 
Merrikhi A. 2014. Frequency assessment of beta-lactamase enzymes in 
Escherichia coli and Klebsiella isolates in patients with urinary tract infection. 
Journal of research in medical sciences : the official journal of Isfahan University 
of Medical Sciences 19:S41-45. 
164. Miethke M, Marahiel MA. 2007. Siderophore-based iron acquisition and 
pathogen control. Microbiol Mol Biol Rev 71:413-451. 
165. Nairz M, Schroll A, Sonnweber T, Weiss G. 2010. The struggle for iron - a 
metal at the host-pathogen interface. Cell Microbiol 12:1691-1702. 
166. Drakesmith H, Prentice AM. 2012. Hepcidin and the iron-infection axis. 
Science 338:768-772. 
167. Skaar EP. 2010. The battle for iron between bacterial pathogens and their 
vertebrate hosts. PLoS Pathog 6:e1000949. 
168. Berger H, Hacker J, Juarez A, Hughes C, Goebel W. 1982. Cloning of the 
chromosomal determinants encoding hemolysin production and mannose-resistant 
hemagglutination in Escherichia coli. J Bacteriol 152:1241-1247. 
 143 
169. Schubert S, Cuenca S, Fischer D, Heesemann J. 2000. High-pathogenicity 
island of Yersinia pestis in enterobacteriaceae isolated from blood cultures and 
urine samples: prevalence and functional expression. J Infect Dis 182:1268-1271. 
170. Perry RD, Fetherston JD. 2011. Yersiniabactin iron uptake: mechanisms and 
role in Yersinia pestis pathogenesis. Microbes Infect 13:808-817. 
171. Brumbaugh AR, Mobley HL. 2012. Preventing urinary tract infection: progress 
toward an effective Escherichia coli vaccine. Expert Rev Vaccines 11:663-676. 
172. Orvis J, Crabtree J, Galens K, Gussman A, Inman JM, Lee E, Nampally S, 
Riley D, Sundaram JP, Felix V, Whitty B, Mahurkar A, Wortman J, White 
O, Angiuoli SV. 2010. Ergatis: a web interface and scalable software system for 
bioinformatics workflows. Bioinformatics 26:1488-1492. 
173. Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome. Genome 
biology 10:R25. 
174. Subashchandrabose S, Hazen TH, Rasko DA, Mobley HL. 2013. Draft 
genome sequences of five recent human uropathogenic Escherichia coli isolates. 
Pathogens and disease. 
175. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. 2008. Mapping 
and quantifying mammalian transcriptomes by RNA-Seq. Nature methods 5:621-
628. 
176. R Development Core Team. 2012. R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. 
177. Kolde R. 2013. Pretty Heatmaps. R package version 0.7.7. 
178. Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream MA, 
Barrell B. 2000. Artemis: sequence visualization and annotation. Bioinformatics 
16:944-945. 
179. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes 
in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640-
6645. 
180. Hagberg L, Engberg I, Freter R, Lam J, Olling S, Svanborg Eden C. 1983. 
Ascending, unobstructed urinary tract infection in mice caused by 
pyelonephritogenic Escherichia coli of human origin. Infect Immun 40:273-283. 
181. Kearney JF, Radbruch A, Liesegang B, Rajewsky K. 1979. A new mouse 
myeloma cell line that has lost immunoglobulin expression but permits the 
construction of antibody-secreting hybrid cell lines. J Immunol 123:1548-1550. 
 144 
182. Gefter ML, Margulies DH, Scharff MD. 1977. A simple method for 
polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic 
cell genetics 3:231-236. 
183. Claflin JL, Hudak S, Maddalena A. 1981. Anti-phosphocholine hybridoma 
antibodies. I. Direct evidence for three distinct families of antibodies in the 
murine response. J Exp Med 153:352-364. 
184. Johnson JR, Kuskowski MA, Gajewski A, Soto S, Horcajada JP, Jimenez de 
Anta MT, Vila J. 2005. Extended virulence genotypes and phylogenetic 
background of Escherichia coli isolates from patients with cystitis, pyelonephritis, 
or prostatitis. J Infect Dis 191:46-50. 
185. Fetherston JD, Bearden SW, Perry RD. 1996. YbtA, an AraC-type regulator of 
the Yersinia pestis pesticin/yersiniabactin receptor. Mol Microbiol 22:315-325. 
186. Rakin A, Schneider L, Podladchikova O. 2012. Hunger for iron: the alternative 
siderophore iron scavenging systems in highly virulent Yersinia. Frontiers in 
cellular and infection microbiology 2:151. 
187. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, 
McWilliam H, Remmert M, Soding J, Thompson JD, Higgins DG. 2011. Fast, 
scalable generation of high-quality protein multiple sequence alignments using 
Clustal Omega. Molecular systems biology 7:539. 
188. Bagos PG, Liakopoulos TD, Spyropoulos IC, Hamodrakas SJ. 2004. PRED-
TMBB: a web server for predicting the topology of beta-barrel outer membrane 
proteins. Nucleic acids research 32:W400-404. 
189. Lukacik P, Barnard TJ, Keller PW, Chaturvedi KS, Seddiki N, Fairman JW, 
Noinaj N, Kirby TL, Henderson JP, Steven AC, Hinnebusch BJ, Buchanan 
SK. 2012. Structural engineering of a phage lysin that targets gram-negative 
pathogens. Proc Natl Acad Sci U S A 109:9857-9862. 
190. Branger CG, Sun W, Torres-Escobar A, Perry R, Roland KL, Fetherston J, 
Curtiss R, 3rd. 2010. Evaluation of Psn, HmuR and a modified LcrV protein 
delivered to mice by live attenuated Salmonella as a vaccine against bubonic and 
pneumonic Yersinia pestis challenge. Vaccine 29:274-282. 
191. Bachman MA, Miller VL, Weiser JN. 2009. Mucosal lipocalin 2 has pro-
inflammatory and iron-sequestering effects in response to bacterial enterobactin. 
PLoS Pathog 5:e1000622. 
192. Bachman MA, Oyler JE, Burns SH, Caza M, Lepine F, Dozois CM, Weiser 
JN. 2011. Klebsiella pneumoniae yersiniabactin promotes respiratory tract 
infection through evasion of lipocalin 2. Infect Immun 79:3309-3316. 
 145 
193. Neilands JB. 1979. The ironic function of bacteriophage receptors. Trends in 
biochemical sciences (Amsterdam. Regular ed.) 4:115-118. 
194. Chan CY, St John AL, Abraham SN. 2013. Mast cell interleukin-10 drives 
localized tolerance in chronic bladder infection. Immunity 38:349-359. 
195. Keeney KM, Yurist-Doutsch S, Arrieta MC, Finlay BB. 2014. Effect of 
Antibiotics on Human Microbiota and Subsequent Disease. Annual review of 
microbiology. 
196. Olesen B, Hansen DS, Nilsson F, Frimodt-Moller J, Leihof RF, Struve C, 
Scheutz F, Johnston B, Krogfelt KA, Johnson JR. 2013. Prevalence and 
characteristics of the epidemic multiresistant Escherichia coli ST131 clonal group 
among extended-spectrum beta-lactamase-producing E. coli isolates in 
Copenhagen, Denmark. J Clin Microbiol 51:1779-1785. 
197. Oteo J, Navarro C, Cercenado E, Delgado-Iribarren A, Wilhelmi I, Orden B, 
Garcia C, Miguelanez S, Perez-Vazquez M, Garcia-Cobos S, Aracil B, 
Bautista V, Campos J. 2006. Spread of Escherichia coli strains with high-level 
cefotaxime and ceftazidime resistance between the community, long-term care 
facilities, and hospital institutions. J Clin Microbiol 44:2359-2366. 
198. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. 2010. 
Escherichia coli sequence type ST131 as the major cause of serious multidrug-
resistant E. coli infections in the United States. Clin Infect Dis 51:286-294. 
199. Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, 
Forde BM, Phan MD, Gomes Moriel D, Peters KM, Davies M, Rogers BA, 
Dougan G, Rodriguez-Bano J, Pascual A, Pitout JD, Upton M, Paterson DL, 
Walsh TR, Schembri MA, Beatson SA. 2014. Global dissemination of a 
multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 111:5694-
5699. 
200. Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S. 
2007. Identification of candidates for a subunit vaccine against extraintestinal 
pathogenic Escherichia coli. Infect Immun 75:1916-1925. 
201. Mattes MJ. 1987. Biodistribution of antibodies after intraperitoneal or 
intravenous injection and effect of carbohydrate modifications. Journal of the 
National Cancer Institute 79:855-863. 
202. Hagan EC, Mobley HL. 2009. Haem acquisition is facilitated by a novel 
receptor Hma and required by uropathogenic Escherichia coli for kidney 
infection. Mol Microbiol 71:79-91. 
203. Russo TA, Carlino UB, Johnson JR. 2001. Identification of a new iron-
regulated virulence gene, ireA, in an extraintestinal pathogenic isolate of 
Escherichia coli. Infect Immun 69:6209-6216. 
 146 
204. Hagan EC. 2009. Iron Acquisition by Uropathogenic Escherichia coli: ChuA and 
Hma Heme Receptors as Virulence Determinants and Vaccine Targets. 
205. Snyder JA, Haugen BJ, Buckles EL, Lockatell CV, Johnson DE, Donnenberg 
MS, Welch RA, Mobley HL. 2004. Transcriptome of uropathogenic Escherichia 
coli during urinary tract infection. Infect Immun 72:6373-6381. 
206. Hagan EC, Lloyd AL, Rasko DA, Faerber GJ, Mobley HL. 2010. Escherichia 
coli global gene expression in urine from women with urinary tract infection. 
PLoS Pathog 6:e1001187. 
207. Giannakopoulos X, Evangelou A, Kalfakakou V, Grammeniatis E, 
Papandropoulos I, Charalambopoulos K. 1997. Human bladder urine oxygen 
content: implications for urinary tract diseases. Int Urol Nephrol 29:393-401. 
208. Shalel-Levanon S, San KY, Bennett GN. 2005. Effect of oxygen, and ArcA and 
FNR regulators on the expression of genes related to the electron transfer chain 
and the TCA cycle in Escherichia coli. Metabolic engineering 7:364-374. 
209. Lane MC, Li X, Pearson MM, Simms AN, Mobley HL. 2009. Oxygen-limiting 
conditions enrich for fimbriate cells of uropathogenic Proteus mirabilis and 
Escherichia coli. J Bacteriol 191:1382-1392. 
210. Cai W, Wannemuehler Y, Dell'anna G, Nicholson B, Barbieri NL, 
Kariyawasam S, Feng Y, Logue CM, Nolan LK, Li G. 2013. A novel two-
component signaling system facilitates uropathogenic Escherichia coli's ability to 
exploit abundant host metabolites. PLoS Pathog 9:e1003428. 
211. Imlay JA. 2013. The molecular mechanisms and physiological consequences of 
oxidative stress: lessons from a model bacterium. Nat Rev Microbiol 11:443-454. 
212. Lee SH, Hava DL, Waldor MK, Camilli A. 1999. Regulation and temporal 
expression patterns of Vibrio cholerae virulence genes during infection. Cell 
99:625-634. 
213. Talaat AM, Lyons R, Howard ST, Johnston SA. 2004. The temporal 
expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl 
Acad Sci U S A 101:4602-4607. 
214. Deriu E, Liu JZ, Pezeshki M, Edwards RA, Ochoa RJ, Contreras H, Libby 
SJ, Fang FC, Raffatellu M. 2013. Probiotic bacteria reduce salmonella 
typhimurium intestinal colonization by competing for iron. Cell host & microbe 
14:26-37. 
215. Koropatkin NM, Cameron EA, Martens EC. 2012. How glycan metabolism 
shapes the human gut microbiota. Nat Rev Microbiol 10:323-335. 
 147 
216. Winter SE, Lopez CA, Baumler AJ. 2013. The dynamics of gut-associated 
microbial communities during inflammation. EMBO reports 14:319-327. 
217. Torres AG, Payne SM. 1997. Haem iron-transport system in enterohaemorrhagic 
Escherichia coli O157:H7. Mol Microbiol 23:825-833. 
218. Lim JK, Gunther NWt, Zhao H, Johnson DE, Keay SK, Mobley HL. 1998. In 
vivo phase variation of Escherichia coli type 1 fimbrial genes in women with 
urinary tract infection. Infect Immun 66:3303-3310. 
 
 
 
 
 
